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She’s a model, and she’s looking good.
You’d like to take her home, that’s understood.
— Kraftwerk, The Model
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Chapter 1
General Introduction
1.1 Introduction
Drug design is almost exclusively an activity of the pharmaceutical industry, and given this
industrial background, research in the field is characterized by a combination of the pragmatic
and the speculative. Novel methods are embraced with great enthusiasm in the hope of finding
shortcuts in the hit-and-miss process of discovering and developing leads, but the perspective
of traditional medicinal chemistry remains central. Computational approaches have reflec-
ted the medicinal chemist’s viewpoint from the beginning, first in the form of chemometric
methods, and later pharmacophore-based approaches. Recent developments in combinator-
ial chemistry, high-throughput screening and molecular biology (genomics, bioinformatics,
proteomics . . . ) are the latest trends threatening to turn tradition upside-down.
The rise of “structure-based (drug) design” (also known as “direct design”, or even “ra-
tional drug design”) was accompanied by similar revolutionary pretensions. The longer term
consequence of this trend has been the growing importance of the viewpoint of the crystallo-
grapher (or structural biologist). This interest in techniques where the structure of the receptor
is pivotal has been encouraged by the demonstrable importance of crystallographic data to the
development of the highly successful HIV-1 protease (HIV-1 PR) inhibitors [250], and lead
compounds for a number of other receptors since [167], coupled to the rapid growth in the
number of “receptors in search of a drug” identified by molecular biology [117]. As always,
the promise of computational approaches is the ability to make accurate predictions about the
activity of novel ligands quickly and cheaply.
A convenient definition of structure-based design is the use of an atomic resolution re-
ceptor structure (presumed accurate) to design small ligands with high affinity. Only the in
vitro biochemical situation is relevant to this viewpoint, and kinetics are neglected. Given
a candidate ligand, specific molecular interactions are considered to be responsible for the
molecular recognition process. Automated structure-based design procedures work with sim-
plified models in the interest of speed, and in practice do not produce high affinity ligands
from scratch. Instead, the aim is to rank collections of compounds as prospective ligands, with
the most highly ranked to be considered by the medicinal chemist as possible leads. Design
therefore remains a process of iterative improvement, with experimental evaluation required
at each step. Once ligands of moderate potency have been found, structural studies of the
ligand–receptor complex by X-ray crystallography or NMR give insight into the binding
mode, more data for computational efforts, and an improved chance of success in the next
iteration.
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The picture of molecular recognition which underlies the principles of structure-based
design, is born out of macromolecular crystallography. The understanding of protein and
DNA structure in terms of hydrogen bonding and shape complementarity has shaped our
ideas of how ligand–receptor complexes fit together with high specificity and affinity. The
flip side of the incredible success of structural biology is that recognition is seen primarily in
static terms, while binding is an equilibrium process where factors such as the displacement
of water from the active site are of great importance. A consideration of these other essential
components of molecular recognition means expanding the principles of ligand design with
techniques and insights from other fields, from the models of chemical physics, to the complex
signalling theories of immunology and cell biology.
Despite a wealth of experimental data from structural biology, and an ever-growing level
of sophistication in computational methods, we are a long way from a workable theory of
molecular recognition. It is generally agreed that well-understood physical laws underlie in-
teractions between biological molecules, but unfortunately this does not imply that testable
predictions can be made, for instance of the association constant of an arbitrarily chosen lig-
and/receptor system. So far, detailed physical models have demanded infeasibly large amounts
of computation to predict relevant, observable properties of the system in question. Neither
have simplified models, within the reach of computation or analysis, been successful in allow-
ing quantitative prediction. Considering the difficulty of predicting the bulk properties of a
pure liquid such as water through simulation, none of this is surprising. Descriptions of mo-
lecular recognition derived empirically have been more illuminating, and have also provided
alternative methods for quantitative prediction. However, experiment regularly produces un-
expected results regarding the affinity or binding mode of novel complexes [53, 153].
1.2 Structure-based design in practice
The development of the HIV-1 protease inhibitors is an informative example of the practice of
structure-based design and the analysis of molecular recognition. HIV protease was identified
as an aspartic protease soon after the HIV genome was sequenced [189], allowing the first lead
compounds to be found quickly without large-scale screening or knowledge of the enzyme
structure. Saquinavir, the first drug to be approved by the US FDA, was developed as a
substrate analogue, without an important contribution from structural information [250]. All
subsequent drugs have been developed with explicit knowledge of the structural basis of HIV
protease inhibition, and more than a hundred crystal structures of enzyme-inhibitor complexes
determined as part of drug development efforts have been released to the public [236].
Information about the molecular recognition of inhibitor molecules by the protease has
been primarily useful as an aid to the intuition of the medicinal chemist. In many cases
(for instance, in the development of Indinavir [64]), structures of a complex were used as
a basis for modelling studies where possible improvements to the inhibitor structure could
be tested against the structural constraints, and additional binding sites could be identified.
Knowledge of the structure of the binding site led to such strategies as the use of symmetrical
inhibitors [89], and inhibitors designed to displace a structural water molecule bound in the
active site [220]. The addition of structural data to the iterative process of development also
gave an important opportunity to check if optimization of the ligand structure resulted in
the hypothesized molecular interactions. The observation that symmetric inhibitors may bind
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to HIV-1 PR in an asymmetric manner led the development effort at Abbott away from
these compounds [250]. In general, the intention was that structural insight would guide the
development process, allowing it to be completed with fewer cycles of trial-and-error. In
view of the rapid appearance of viral resistance, new structure-based computational methods
to design agents effective in the face of protease mutation [194] are also likely to attract much
interest.
Computational techniques have played a fairly minor role in the development of marketed
HIV-1 protease inhibitors, although many details of the story are still trade secrets. Pharmaco-
phores suggested by modelling and crystal structures have been used for prospective searching
of databases [128], and a de novo technique was used to find appropriate substituents to fill
a binding sub-site in one effort at Agouron Pharmaceuticals [80]. The predictions from the
available computer-aided design techniques are not reliable enough to make them the guiding
principle of the development process, but rather one possible source of ideas for better leads.
So far, analysis of the unprecedented quantity of structural data from HIV-1 PR–inhibitor
complexes has not revealed any novel principles of molecular recognition. The enzyme is
promiscuous and binding sub-sites can accommodate groups of various sizes [248]. Unlike the
natural polypeptide substrate, most inhibitors are hydrophobic, and hydrophobic interactions
appear to be the dominant factor in determining affinity [250]. Similar observations were
made in a detailed structural and thermodynamic study of the binding of Lysine-X-Lysine
tripeptides to the oligopeptide-binding protein OppA [52]. The OppA binding site for the
amino acid “X” undergoes little structural change on binding, but adapts readily to different
sidechains through the intermediation of bound water molecules and ions. Evidently, the
binding equilibrium involves numerous compensatory effects, making prediction of the net
balance and the ultimate affinity extremely difficult.
Two unusual features of the HIV-1 PR active site are the presence of a structural water
molecule, thought to play a role in substrate binding and catalysis, and shifted pKas for the two
catalytic aspartate residues. Displacement of the water molecule has been used as a strategy
for the development of highly specific ligands [128, 129], with one compound in this series,
DMP450, still in clinical trials [226]. The shifted pKas of the aspartate residues are important
in determining the affinity and pH-dependence of inhibitor and substrate binding, as almost
all ligands hydrogen bond to at least one of these groups [250].
1.3 Computational approaches
Automated methods for structure-based drug design are not mature enough to replace exist-
ing practices, but new approaches and computer programs continue to appear. Most work
falls into the categories of de novo design, docking, and scoring. De novo design entails the
automatic design of novel ligands intended to bind a given receptor with high affinity, and
is the most difficult of the three problems. While de novo methods have had some successes,
such as in the optimization of a influenza virus sialidase inhibitor [113], most methods have
not been subjected to statistically meaningful experimental evaluation. An area where more
experimental evaluation has been done is the application of structure-based design techniques
to combinatorial libraries. A library of prospective cathepsin D inhibitors designed in this way
contained many more compounds with an IC50 of micromolar or better than a standard lib-
rary of the same monomers [122], and a nanomolar thrombin inhibitor was discovered using
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a similar approach [168].
Docking and scoring are complementary methods which split the problem of ligand bind-
ing into two simpler subproblems. For a receptor of known structure and a ligand, docking
involves finding the bound configuration of the ligand and receptor, assuming a specific inter-
action of reasonable affinity, while scoring involves estimating the affinity of the ligand, given
a particular bound configuration. Most docking and scoring methods are empirical approaches
involving extrapolation from known ligand–receptor complexes.
The binding process can also be simulated using physically accurate atomic potential func-
tions, and these simulations will yield information about the binding mode and affinity. Cur-
rently available force fields are probably sufficient for these free energy simulations, but the
calculations are too slow for most applications (see Chapter 4 for further discussion). Practical
free energy simulations to compare the affinities of different ligands at a particular receptor
have most of the restrictions of empirical scoring approaches, although they are considered to
be more accurate. In particular, the bound configuration must be known and used as the start-
ing point of the simulation, or the results converge unreasonably slowly. The computational
and technical demands of simulation approaches has meant that docking and scoring methods
have received attention as faster, simpler alternatives.
1.3.1 Scoring
Quantitative Structure-Activity Relationship (QSAR) methods were the forerunner of many
of the current scoring techniques. Applications of QSAR demonstrated that molecular struc-
ture could be quantitatively related to pharmacological activity, and that these relationships
could be used in drug development. While the success of QSAR inspired interest in compu-
tational approaches to drug design, its restriction to one- and two-dimensional properties of
the ligand gave rise to efforts to incorporate three dimensional structure into activity predic-
tions. Growing availability of receptor structural data and the development of docking tech-
niques enabled the interactions between ligand and receptor to be used as the starting point
for scoring. Regression-based methods, exemplified by Bo¨hm’s scoring functions [29,30], are
a structure-based outgrowth of QSAR techniques.
The theoretical basis of QSAR analysis is the presumed existence of a linear free-energy
relationship between a physicochemical descriptor of a molecule (such as log P, the octanol-
water partition coefficient) and its affinity for a receptor [94]. These relationships are quantified
by regression analysis, and can be highly predictive for closely analogous series of compounds.
The Bo¨hm approach replaces the physicochemical descriptors with a collection of quantities
calculated from the geometry of the ligand–receptor complex, which are chosen to capture the
most important interactions between the two, such as hydrogen bonds. With an appropriate
set of interaction descriptors, and a representative set of complexes to perform the regression
on, an equation with general applicability should result. Ideally, the coefficients of the equation
should be consistent with an intuitive understanding of the molecular recognition process.
Scoring using the master equation approach often uses the same functional form as re-
gression approaches, namely a linear combination of interaction descriptors, although the
derivation of these scoring functions is quite different. The underlying assumption is that
a highly simplified description of molecular recognition will be sufficient to make useful af-
finity predictions [4]. The simplifications are typically chosen on the grounds of expediency
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and may include: rigid receptor and ligand; neglect of solvation effects; fixed contributions
from hydrogen bonds; neglect or rough approximation of entropic effects; simple estimates
of hydrophobic binding; continuum approximations to electrostatic energies. The most im-
portant assumption is that the free energy of interaction can be decomposed into independent
components, such as electrostatic energies, entropies, hydrophobic interactions, and so on.
Methods which involve minimization and analysis of force field interaction energies are also
in the category of master equation approaches.
1.3.2 Docking
The docking problem has been approached in a variety of ways. Docking is essentially a matter
of searching and optimization, and is a straightforward geometric problem when both ligand
and receptor are treated as rigid. Consideration of the flexibility of ligand and/or receptor
involves many additional degrees of freedom, making heuristics necessary to limit the extent
of the search. The quantity to be optimized (the “interaction energy”) also presents some
difficulties. D, one of the oldest and most widely used programs, is based on a simple
on-off model of steric complementarity [126]. Potential functions similar to those used for
simulations (such as A and C) have been popular, but the need for an implicit
treatment of solvation has resulted in the development of energy terms similar (or identical)
to the scoring functions described above. Small, rigid ligands with high affinity can be docked
easily to rigid receptors by any of a variety of methods, but ligands such as peptides which are
highly flexible are a challenge to even the most sophisticated docking algorithms.
Essentially important to these techniques are the models of ligand and receptor themselves.
At a basic level, these function as a convenient substitute for real-life metal or plastic molecu-
lar models, giving immediate visual-spatial insight into structure in an uncomplicated way.
Quantitative studies make more demands on the physical realism of the model, including the
accuracy of the potential energy function. The most popular protein forcefields have been
extensively evaluated for their ability to reproduce conformational equilibria [23], but may be
lacking in other aspects which are important for accurate simulations, for instance polarisation,
and the strength and directionality of non-bonded interactions. Notably, the most accurate
free energy simulations have required additional optimization of potential functions [51, 131].
Perhaps more troubling, the experimental basis of models is sometimes patchy. Structural data
from X-ray crystallography or NMR studies are of limited resolution and completeness, and
these shortcomings should be considered when building models [104]. Details such as solva-
tion and protonation state need to be addressed, often without any experimental data. All of
these uncertainties make the validation of models a vital (if awkward) aspect of work in this
field.
1.3.3 The future
The failings of current methods for computing ligand–receptor interactions will be corrected
at least in part by developments in related fields. Most importantly, faster computers will
allow larger and larger systems to be analysed using brute force methods, as will innovations in
numerical algorithms. The accumulation of accurate structural and biochemical data will allow
better calibration of force fields and scoring functions, and an improved ability to distinguish
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between good and bad models. Improved experimental techniques for measuring pKas will
allow more accurate modelling of protonation states.
The refinement of force fields and (implicit) solvation models will also be an important
area of advancement. Efficient and accurate implicit solvation schemes will improve the speed
of many types of simulations, and bring some excessively costly calculations within reach. In
the absence of accurate experimental data, simulations using more detailed levels of theory can
be used in the development of models at coarser levels of description. In this way, quantum
chemical calculations provide the parameters for potentials for atomistic simulations, and atom-
istic simulations provide the parameters for implicit solvent simulations, and so forth [237].
Of course, the impact of new methods is difficult to predict. More efficient simulation and
free energy formalisms are very desirable, and the consequences of recent developments in this
area, such as linear response approaches [15], advanced Monte Carlo (MC) techniques [77],
and generalised ensemble methods [134] are not yet clear. Methods developed in the chemical
physics community take time to find applications in biological problems, often due to the
extra implementation work needed for the more complex biomolecular models. However,
the exceptional properties of biological molecules may require more than just the adaptation
of existing chemical and physical knowledge, as research in protein folding has demonstrated.
Workable models often depend on careful consideration of how different aspects of the system
may be simplified [73, 158]. In this vein hybrid or hierarchical models can be useful, as
demonstrated by the MBO(N)D approach to molecular dynamics [45].
An area of recent intense interest has been the development of knowledge-based potentials
for scoring [59, 87, 157, 165, 166, 206, 231]. This way of constructing effective potentials was
popularized in the field of protein-folding. The growth in the number of ligand–receptor
complexes found in the Protein Data Bank (PDB) [25,26] has made these potentials a practical
and perhaps more accurate substitute for regression-based scoring functions. Although the
statistical-thermodynamic basis of existing knowledge-based potentials is not entirely rigorous,
it is tempting to imagine the possibility of bridging the gap between empirical and physical
descriptions of molecular recognition through the concept of potentials of mean force. Further
investigation of details such as atom-typing, hydrogen atom placement, and treatment of the
solvent, will reveal the possibilities and limitations of these methods.
Developments in computational approaches to molecular recognition are likely to be
gradual, considering that the vital ingredient of validation is laborious and time-consuming.
The CATFEE initiative [192] for the competitive, blind testing of free energy prediction
techniques is an important development in this respect. Advances in experiment, theory and
implementation reinforce one another, but feedback between these specialized fields takes
time. Looking at the developments over twenty years of docking, fifteen years of protein free
energy simulations (with a million-fold increase in simulation time scales along the way) and
a decade of scoring, it seems likely that the next ten years will see big improvements in our
ability to predict binding affinities.
1.4 Scope of thesis
This thesis describes various computational approaches to the analysis of ligand–protein mo-
lecular recognition. The aim is to evaluate a number of methods with particular attention to
possible applications in computer-aided structure-based drug design. Addition of extra detail
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to computer models regarding protonation and electrostatics, and the use of a novel simula-
tion technique, configurational bias Monte Carlo sampling, are the basis for this attempt to
gain more accuracy and insight from scoring and docking methods. HIV-1 protease and its
inhibitors were chosen as the model system for these studies because of the ready availability of
many X-ray crystal structures, and the special role of protonation in the mechanism of action
and inhibition. HIV-1 protease is also a small, straightforward enzyme, as demonstrated by its
complete chemical synthesis [49, 198], simplifying the task of modelling.
The starting point for investigating the protonation state and electrostatic characteristics
of HIV-1 PR was a series of pKa calculations on enzyme–inhibitor complexes, using the
finite-difference Poisson-Boltzmann approach (Chapter 2). Thermodynamic linkage of the
protonation of active site residues with inhibitor binding means that a portion of the free
energy change on binding can be ascribed to a change in protonation, and the size of this
effect may vary between inhibitors. The results of the pKa calculations allow models to be
built with appropriate protonation, and correction of KD values for proton linkage effects.
Models of the complexes and corrected KD data were used to analyse electrostatic com-
plementarity and the relationships between structural parameters and affinity (Chapter 3). A
regression analysis drawing on the concepts of the Bo¨hm scoring functions and master equa-
tion approaches was used, and a comparison was made with results from other scoring and
simulation literature about HIV-1 PR. In conclusion the consequences for our understanding
of molecular recognition in this system are discussed.
Some of the shortcomings of scoring functions, particularly the difficulty of estimating the
size of the entropy change on binding, are avoided in simulations of ligand–receptor bind-
ing using Monte Carlo or molecular dynamics sampling. Configurational bias Monte Carlo
(CBMC) sampling is much more efficient than MD or Metropolis MC for simulating the
adsorption behaviour of simple polymers, and recently has proven useful for the conforma-
tional analysis of simplified polypeptide models. A CBMC technique was developed for the
detailed atomic potentials normally used for protein and peptide simulations, and its accuracy
and efficiency was validated (Chapter 4).
As well as conventional simulation applications, CBMC can be applied to docking. The
efficiency of CBMC in sampling internal degrees of freedom should be advantageous for
docking flexible molecules. Docking of a tripeptide inhibitor to a rigid HIV-1 PR model
was attempted using CBMC and the results compared with other docking algorithms, such as
the MC simulated annealing method of AutoDock [88] (Chapter 5). The parallel tempering
method [82], similar to simulated annealing, was used to improve sampling. The efficiency of
CBMC for this type of simulation was also further analysed.
Chapter 2
Proton linkage in HIV 1 PR–inhibitor
complexes
2.1 Introduction
Structural biology provides a first-rate vantage point for looking at structure-activity rela-
tionships of drugs. Detailed and accurate models of receptor proteins make many categories
of qualitative and quantitative analysis of ligand–receptor binding possible, from empirical
QSAR approaches, to physically realistic simulations. Nonetheless, construction of a model
from high-resolution X-ray or NMR data requires a number of assumptions about details
absent from the structural data. For models based on X-ray data, the presence and location
of protons is missing from the experimental picture. Sometimes precise placement of pro-
tons makes no difference to the usefulness of the model, but this is not so if the electrostatic
characteristics of the protein are to be considered.
This study aims to calculate apparent pKas for HIV-1 PR/inhibitor complexes, and make
predictions of the nature and size of proton linkage phenomena in these systems. An adequate
description of the protonation state is a prerequisite for QSAR studies and accurate modelling
of complexes, given that these may represent a sizeable perturbation of “standard” conditions,
and a substantial correction to the free energy changes involved. Experimental results showing
pH dependence of inhibitor binding indicate this to be the case for a number of the ligands
considered.
HIV-1 PR inhibitor data has been used in many QSAR/scoring studies without reference
to possible shifts in protonation state in the active site. The pH at which inhibition constants
are measured, and at which crystal structures were determined is also rarely taken into account.
It may be that the degree of uncertainty inherent in such studies is bigger than the effect of
these factors, but on the other hand, their neglect may contribute to the inaccuracy of these
methods.
2.1.1 Electrostatic interactions and binding
Molecular recognition observed in crystal structures of ligand–receptor complexes (reviewed
from a drug design perspective in [31]) can often be explained in terms of electrostatic inter-
actions. The importance of hydrogen-bonding to recognition is well-known, and there are
many examples where a certain pattern of hydrogen-bonding between ligand and receptor
is thought to be essential for specificity. Hydrogen-bonding can be adequately described by
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classical electrostatic interactions between point charges on atomic nuclei, at least at the level
of accuracy expected in general-purpose forcefields. Electrostatic interactions between groups
bearing a formal charge (for instance, in salt bridges) also have a clear role in molecular recog-
nition.
The nature of the contribution of electrostatic interactions to the free energy change on
binding is less clear. Where these interactions appear to be close to optimal, for instance
in the hydrogen-bonding between streptavidin and biotin, it is hypothesized that they are a
driving force for association [246], although unravelling the precise contribution has proven
difficult [218]. More generally, the net contribution of interactions between polar groups
depends on the balance between the strength of the interactions seen in the complex and
the solvation energy of the same groups when the species are free in solution, and as seen
in studies of thermolysin inhibitors, loss of a hydrogen bond does not necessarily lead to a
decrease in affinity [162]. There is no clear consensus on a simple, general description of these
contributions, but at a coarser level of description, a term proportional to the polar surface area
buried on complex formation appears in some empirical descriptions of the thermodynamics
of binding (e.g. [140]).
In a number of cases, the influence of electrostatic interactions on binding kinetics is
clear. Electrostatic “steering”, where oppositely charged ligand and receptor attract each other
at long range, is the mechanism responsible for the diffusion-limited catalytic rate of the
oxidation of the superoxide anion by superoxide dismutase [101]. However, these phenomena
are not observed in all interactions, and a number of enzyme–substrate systems are known
where like charges in ligand and receptor might be expected to impede the binding process
[133].
2.1.2 The influence of proton location on electrostatics
The electrostatic behaviour of proteins and peptides is primarily determined by the precise
location of covalently bound hydrogens, or more loosely, protons. Hydrogen bonds are dir-
ectional, so the orientation of hydroxyl rotamers, unclear at the resolution of typical protein
X-ray structures, determines the possibilities for interaction. As hydroxyl groups function
simultaneously as hydrogen bond donor and acceptor, optimization of the hydrogen bond
network which arises when a number of donating and accepting groups interact at an in-
terface, involves the consideration of a large number of possible configurations. Analysis of
ligand–receptor interfaces indicates that high-affinity complexes rarely contain hydrogen bond
donors which do not make a hydrogen bond [147, 256], suggesting that this situation is ac-
companied by a significant free energy penalty.
The location of protons also depends on the ionisation state of titratable groups, and the
configuration of tautomers. As these protons are also invisible to X-ray diffraction in most
practical cases, the formal charge and hydrogen bond donor/acceptor status of many groups
in a protein is ambiguous. Experimental pKas for groups such as carboxylic acids are a guide,
but the apparent pKa of titratable groups in proteins depends on the protein environment, and
may not correspond to that measured for model compounds.
Building molecular models of proteins therefore requires information in addition to that
provided by X-ray structures. Where this information about hydrogen bonding and pro-
tonation is unavailable from experiments, assumptions or predictions must be used instead.
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L +R +H+
11G◦b
1Kb
//
f 1G◦p
f Kp

L–R +H+
b1G◦p
bKp

L +R–H+
21G◦b
2Kb
// L–R–H+
Figure 2.1: Thermodynamic cycle showing a simple linkage scheme for the binding of a ligand
(L) to a receptor (R). Superscripts f and b refer to the free and bound states, subscripts p and
b refer to the protonation and binding processes, and superscripts 1 and 2 refer to the binding
of the deprotonated and protonated forms of the ligand, respectively.
Automated procedures exist for optimization of hydrogen bonding networks (e.g. [103]), and
these are adequate for many purposes. Prediction of protonation states is more difficult, and
a number of approaches have been proposed. Prediction of apparent pKas by simulation of
electrostatic interactions between residues is the best characterized of these.
2.1.3 pH effects
Biochemical processes are influenced by the pH of the medium in which they take place.
At extremes of pH, proteins unfold and enzymes cease to function. Within these extremes,
the rate of enzymatic catalysis has been observed to depend on pH, with a maximal velocity
at a particular pH. The binding of inhibitors to enzymes can also be pH-dependent. In
these situations, where an equilibrium process, such as binding, is pH-dependent, then that
equilibrium is thermodynamically linked to the protonation state.
The nature of this linkage can be described in a free-energy cycle and the associated
expressions for equilibria (Figure 2.1). This represents the simplest case, with linkage to a
single protonation site. When multiple protonation equilibria are linked, this more complex
situation is described by the binding polynomial formalism [83, 197]. Linkage can also be
described as a binding-related shift in the apparent pKas of the titratable groups in ligand
and/or receptor. When these pKa shifts are large, the free energy of protonation will be a
large component of the free energy of binding at certain pH values. An alternative description
is that binding of the ligand is accompanied by the release or uptake of protons, which is
associated with a pH-dependent free energy change.
Following the scheme for a single proton linkage given in Figure 2.1, the observed asso-
ciation constant, Kobs, as a function of pH, is given by
Kobs =1 Kb
1 + 10(pKa )b−pH
1 + 10(pKa ) f −pH (2.1)
where (pKa)b = log10(bKp ) and (pKa ) f = log10( f Kp ) .
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2.1.4 Experimental pKa measurements
The titration curve of a protein is the result of the contributions of numerous titratable groups.
Fitting to this curve gives a series of effective pKas for the protein, which in the absence of
other information cannot be assigned to particular amino acid residues. Additional experi-
mental techniques and knowledge of protein structure may allow complete assignment, as in
the case of hen egg-white lysozyme [127]. Unambiguous assignment of an apparent pKa is
possible in an NMR titration experiment, where the pH-dependence of the chemical shift of
a group adjacent to the titratable proton is observed (e.g. measurements of hen and turkey
egg-white lysozymes [19]).
NMR titration experiments can be performed in the presence of a bound ligand, making
measurement of binding-related shifts in apparent pKa possible. NMR studies of proton
linkage along these lines have been done for a small number of HIV-1 protease–inhibitor
complexes, examining the titration behaviour of the active site aspartyl dyad [214, 244, 257].
Surface plasmon resonance and isothermal titration calorimetry are also suitable techniques for
this type of experiment, if the pKas can be assigned successfully [159, 254, 255].
Protein titration in the crystal state has been analysed by atomic resolution (< 1.2 A˚) X-ray
crystallography in an innovative study which appeared in 1999 [24]. Diffraction data collected
from RNase A crystals at six different pH values allowed the locations of titrating protons
to be resolved, and so pKa values for most of the histidine residues could be determined.
Concerted, pH dependent structural changes involving the rearrangement of hydrogen bond
networks could be observed, as well as alternate side chain conformations associated with
different protonation states.
2.1.5 pKa prediction
pKas for proteins can be predicted quite well by calculations using detailed protein structure
models. Absolute pKas cannot be predicted reliably, but prediction of shifts from experiment-
ally determined standard values (e.g. for model compounds with a single titratable group) is
possible. Workable calculations rest on the assumption that electrostatic interactions alone are
responsible for pKa shifts, an approximation which appears to be accurate in comparison to
the other simplifications made in the calculation. Unsurprisingly, these electrostatic interac-
tions are strongly influenced by the aqueous environment of the protein, the effect of which
is usually approximated by dividing the system into media of low and high dielectric constant,
for the protein and solvent respectively.
The most accurate well-characterized protocol for pKa determination gives predictions
with a RMS deviation from experimental values of about 0.7 pKa units, compared to a typical
experimental accuracy of 0.1 pKa units [12]. Assumption of “average” pKas for all residues (the
“null hypothesis”) results in an RMSD of 1 pKa unit, slightly worse than calculation (though
RMSD may not be the best indicator of performance) [12]. Errors in predicted pKas are
not evenly distributed between residues, however, and the predicted pKa for certain residues
may be completely wrong. Given the many uncertainties and approximations inherent in the
method, explaining these errors is difficult.
These pKa prediction calculations can reproduce large pKa shifts in a number of systems.
Often these are residues associated with catalytic activity in an enzyme, such as in hen egg-
white lysozyme. Recently, calculations were applied to a system where a large pKa shift occurs
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AH(g)
1G◦g
//
1Gw (AH)

A−(g)
1Gw (A
− )

+ H+(g)
1Gw (H
+ )

AH(w)
1G◦w
//
1GAHtransfer

A− (w)
1GA
−
transfer

+ H+(w)
AH(p)
1G◦p
// A− (p) + H+(w)
Figure 2.2: Thermodynamic cycles showing breakdown into free energy contributions to the
pKas of AH(w) and AH(p).
on binding, namely HIV-1 protease and a number of its inhibitors [227]. Calculated pKas
agreed well with those that have been experimentally measured. Puzzlingly, both experimental
and calculated pKas gave a prediction of proton linkage while experimental measurement
found no pH-dependence of binding. This suggests that the global pH-dependent behaviour
of proteins may depend on factors which are difficult to identify.
2.1.6 Theory
The brief theoretical introduction that follows reproduces the formulation found in the review
of Briggs and Antosiewicz [35]. A scheme for the free energy changes in the protonation
equilibria of proteins is shown in the thermodynamic cycle in Figure 2.2. The group AH is
considered in the gas phase, AH(g), as an isolated species in water, AH(w), and as a subunit
of a protein, AH(p). The standard free energy change for the deprotonation of AH(w), 1G◦w ,
can be defined in terms of the gas phase proton affinity of the group, −1G◦g , the solvation free
energies of the group in the protonated and deprotonated states, 1Gw(AH) and 1Gw(A
−),
and the solvation energy of the proton 1Gw(H
+). This in turn defines the absolute pKa of
AH(w) (defining the conversion factor k ≡ (RT loge 10)−1):
pK (w )a = k1G◦w = k[1G◦g + 1Gw (A− ) − 1Gw (AH) + 1Gw (H+ )]
All of these quantities can be predicted by simulation, but no accurate estimates, either cal-
culated or experimental, are available for the proton solvation free energy. As the illustrated
thermodynamic cycle is the most workable route to prediction, this means that absolute pKas
such as pK (w )a can only be determined experimentally. Simulations do provide a reasonably
reliable route to relative pKas, allowing the pKa of the group in protein environment to be
predicted based on the (experimental) isolated pKa in water, a quantity known from model
compounds. The relationship can be seen in the lower cycle in Figure 2.2, and gives:
pK (p)a = pK (w )a + k(1GA
−
transfer − 1GAHtransfer ) = pK (w )a + k(1GAH,A
−
protein − 1GAH,A
−
water ) (2.2)
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The terms 1GAH,A
−
protein and 1G
AH,A−
water do not appear in the illustrated free energy cycle, and are
the free energy differences between protonated and deprotonated states (i.e. the ionization en-
ergies) in the protein and water environments, which are more easily accessible to simulation,
and are typically used instead of the transfer energies.
The definition of these free energy changes requires some further description. The stand-
ard free energy change of protonation of the isolated group in water, 1G◦w, is related to the
equilibrium concentrations of the species by the usual expression
exp
1G◦w
RT
= [AH]
[A−][H+]
which using the definitions
pH ≡ − log10[H+] and pK (w )a ≡ k1G◦w
gives
log10
[AH]
[A−]
= pK (w )a − pH
Assuming a Boltzmann distribution for the relative concentrations of the species [AH] and
[A−],
[AH]
[A−]
= exp −1G
RT
giving
1G = k−1(pH − pK (w )a ) (2.3)
that is, the free energy of the protonated state relative to the deprotonated state at arbitrary
pH.
Assuming linear superposition, the combination of Equations 2.2 and 2.3 allows the free
energy of an arbitrary ionization state of the whole molecule at a particular pH, relative to
the neutral protein, to be written as a function of the model compound pKas, the ionization
energy difference terms, Gii, and an interaction matrix, Gi j :
1G(pH, x1, . . . , xM ) = k−1
M∑
i=1
xiγi(pH − pK (w )i ) +
M∑
i=1
xiGii +
M−1∑
i=1
M∑
j=i+1
xix jGi j
for a protein with M ionizable groups, where xi is 1 if the group i is ionized, and 0 if it is
neutral, and γi is −1 for acidic groups and +1 for basic groups.
The interaction free energy matrix, Gi j , can be calculated from the electrostatic free en-
ergies of interacting pairs of titratable residues in the protein. Specifically,
Gi j = 1Gelectrostaticprotein,i, j − (1Gelectrostaticprotein,i + 1Gelectrostaticprotein, j )
where each 1G term refers to the electrostatic free energy change associated with the ion-
ization of a group or pair of groups, in an otherwise neutral system of protein and solvent.
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As the free energy changes are calculated relative to the model compound ionization equilib-
rium, additional terms give the required energy differences as defined in Equation 2.2 (also
known as the self-energy terms), and are conventionally assigned to the diagonal elements of
the interaction matrix:
Gii = 1Gelectrostaticprotein,i − 1Gelectrostaticmodel,i
with the model compound ionization energy term calculated for an isolated group in water.
Ionization states for the groups of interest can be derived from the Boltzmann average
of states over the energy levels. For systems with many titrating groups, a full enumeration
is impractical, so a Metropolis Monte Carlo simulation or some variation of a mean-field
approximation is used. The apparent pKa for a group is the pH at which it is on average 50%
ionized. A robust method to determine this is simply to perform a series of MC simulations at
various pH values.
In this chapter, pKa predictions were made using the “mesoscopic” continuum model of
protein electrostatics, in which the electrostatic potential is calculated from the finite difference
solution of the Poisson-Boltzmann (PB) equation. In this model the protein is represented as a
low-dielectric solute, bounded by its solvent-accessible surface, embedded in a high-dielectric
electrolyte. The charge density of the protein is represented by point charges fixed at the
positions of the protein atoms, with ions in the electrolyte obeying a Boltzmann distribution.
The physical significance of the protein dielectric constant in this model has been debated,
but in a general sense it can be seen as an adjustable empirical screening parameter, which
compensates somewhat for the neglect of dipole rearrangement [35]. Another method with
similar accuracy to the one used here is the protein dipole-Langevin dipole (PDLD) model
[245].
2.1.7 HIV-1 protease
HIV-1 protease (HIV-1 PR) is a viral enzyme vital for the life cycle of the human immunode-
ficiency virus [124]. The protease is not very specific, but has some preference for cleavage
sites in the viral gag and gag-pol polyproteins. The active protease is a symmetric homodimer
with the single active site located in a central “tunnel” penetrating the protein (see Figure 2.3).
One side of this tunnel is formed by two β-loops (named D1 in the standard nomenclature),
one from each monomer, which meet close to the symmetry axis of the enzyme. NMR
studies of the apoenzyme in solution show that these loops (or flaps) are very flexible [112],
with the otherwise almost inaccessible active site regularly exposed by disordered flap con-
formations. Crystal structures of the apoenzyme have an ordered, “open” configuration for
the flaps, while complexes have the flaps in tighter, “closed” arrangement, with the tips of the
flaps moving about 7 A˚ [248].
The backbone conformation of the enzyme in enzyme–inhibitor complexes is constant
between many crystal structures with different inhibitors, and for almost all inhibitors the
interactions between ligand and receptor are similar. The binding pockets for the ligand
sidechains have been classified and labelled, with sites numbered starting adjacent to the scissile
amide bond of the bound substrate. The pocket on the N-terminal side is labelled S1, and
on the C-terminal side S1′, following the nomenclature of Schechter and Berger [196]. Like-
numbered pockets are formed by identical residues because of the symmetry of the enzyme.
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Figure 2.3: Ribbon diagram of the HIV-1 PR dimer with a bound inhibitor
Almost all complexes feature a buried water molecule bridging the NH groups of Ile50/Ile50
′
and CO groups at P2 and P1
′
of the inhibitor.
The catalytic activity of HIV-1 protease depends on a dyad of aspartic acid residues central
in the active site, Asp25 and Asp25′. This makes it a member of the wider family of aspartic
proteases, which have a characteristic two-domain structure (though retroviral proteases such
as HIV-1 PR are smaller and are the only enzymes known to be symmetric homodimers).
As observed in other proteases, the catalytic activity of HIV-1 PR is pH-dependent, with an
optimum catalytic constant at pH 5–6 [109, 110]. The pKas of the catalytic aspartate residues
are known to be shifted substantially from the expected values ∼4, to a distinct pair of apparent
pKas for the dyad as a whole, measured as ∼ 3 and ∼ 6 [109,110,227]. The distance between
the inner oxygen atoms of the coplanar carboxylate groups observed in the crystal structure of
the apoenzyme indicates the presence of an acidic proton bridging them [132, 170, 215, 249].
Inhibitors of HIV-1 PR are clinically useful drugs in the treatment of HIV infection. The
development of these drugs was largely the result of structure-based ligand design, and crystal
structures of HIV-1 PR-inhibitor complexes were of primary importance. Due to this history,
there have been an unprecedented number of such crystal structures determined, making the
HIV-1 PR system a particularly interesting one for modelling studies of molecular recognition.
Although the inhibitors of HIV-1 PR are structurally diverse, a number of features are
common to almost all of them. Many of them were designed using a peptidomimetic strategy,
beginning with a transition-state analogue of the natural peptide substrate. Despite this, the
inhibitors with high affinity owe this to strong hydrophobic interactions, with relatively few
hydrogen bonds. The strength of hydrophobic interactions is determined by the degree of
steric complementarity, but describing this quantitatively is difficult.
Nonetheless, an adequate description of the electrostatic contributions to binding, and in
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PDB inhibitor res. R pH Ki pH ref.
code A˚ factor crys. nM ass.
1a30 Glu-Asp-Leu 2.0 0.189 4.2 52000. 4.25 [139]
1aaq Psi 2.5 0.190 5.0–5.6 4. 6.0 [65]
1hbv SB203238 2.3 0.177 5.4–5.6 430. 6.0 [105]
1hpv VX-478 1.9 0.192 5.4 0.6 NA [123]
1htf GR126045 2.2 0.193 3.4–5.4 8. 6.0 [102, 115]
1htg GR137615 2.0 0.190 3.4–5.4 0.21 6.0 [102, 115]
1hvi A-77003 1.8 0.181 6.2 0.012 6.2 [107]
1hvj A-78791 2.0 0.158 6.2 0.004 6.2 [107]
1hvk A-76928 1.8 0.177 6.2 0.011 6.2 [107]
1hvl A-76889 1.8 0.186 6.2 0.112 6.2 [107]
1hvr XK263 1.8 0.193 5.4 0.31 5.5 [5]
prmvt101 MVT-101 2.0 0.154 5.4 780. 6.6 [155, 156]
5hvp acetyl-pepstatin 2.0 0.176 5.0–5.4 35. 5.0 [74, 190]
7hvp JG-365 2.4 0.146 5.4 0.24 6.5 [220]
8hvp U-85548e 2.5 0.138 5.4 3. 5.0 [114, 138]
9hvp A-74704 2.8 0.177 5.4 4.5 4.7 [70]
Table 2.1: PDB codes and details of the HIV-1 PR-inhibitor crystal structures. The prmvt101
coordinates are an improved refinement at higher resolution of the complex in PDB 4hvp,
and have not been deposited in the PDB (see text). The Ki assay pH for VX-478 is not
documented. Ki values for GR126045 and GR137615 are scaled IC50 values.
particular, interactions with the catalytic aspartate residues, is important to understanding the
affinity of these compounds. For many inhibitors, binding is known to be pH-dependent
[74, 107, 123, 139], indicating that pKa shifts take place on binding, and in a few cases, the
apparent pKa of the Asps has been determined experimentally for the complex, with substantial
shifts observed [214, 244, 257]. A detailed experimental study of inhibitor binding to another
aspartic proteinase, plasmapepsin II, using isothermal titration calorimetry found evidence for
binding-related pKa shifts of the catalytic aspartates, as well as the expected proton linkages
[255]. The size of the contribution to the total free energy change of binding is unknown for
most ligands, and as in the case of the binding of DMP-323 [227] the relationship between
observed or calculated pKa shifts and actual proton linkage may not be straightforward.
2.2 Methods
2.2.1 Modelling
Structures of HIV-1 PR complexed with inhibitor were taken from the Brookhaven Protein
Databank [25,26] and are listed in Table 2.1. Atom names were checked with W C
[104] and corrected where necessary. Only structures with a resolution of 3 A˚ or better, and
with an R factor of 0.20 or less, were used. The list of structures used is a revised version of
the list of HIV-1 PR complexes appearing in the scoring studies of Eldridge et al. and Moret
et al. [69, 161]. The complex with the inhibitor MVT-101, available as structure 4hvp in the
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label D25 Oδ1 D25 Oδ2 D25
′
Oδ1 D25
′
Oδ2 net charge
00 -2
10 + -1
01 + -1
20 + -1
02 + -1
11 + + 0
22 + + 0
12 + + 0
21 + + 0
Table 2.2: Dyad protonation states. Oδ1 and Oδ2 are the inner and outer oxygen pairs of the
dyad, respectively. In the apoenzyme and in symmetrical complexes the states 10-01, 20-02,
and 12-21 are equivalent.
PDB, was reported by the author to be in error [155], and re-published with an improved
refinement, so in this case the newer coordinates were used [154]. Minor differences in
sequence between the various HIV-1 PR structures did not involve ionizable residues in the
vicinity of the active site.
The complexes were prepared in Insight 2000 [160]. Missing sidechains were added and
water molecules and ions were removed, except for the groove water when present. Where
alternative ligand conformations were given, the one with the highest occupancy was chosen
for modelling (1htf: conformation 1; 1htg: conformation 300; prmvt101: conformation b;
5hvp: conformation 1). L analysis [241] of the active site was used to identify probable
hydrogen bonds, and this information was used to place the protons of the catalytic aspartate
dyad in the fully protonated state. An additional check was performed for possible hydrogen
bonds where a carboxylic acid group acted as a donor. Other hydrogen atoms were given
initial positions by Insight, and all hydrogen positions were subjected to 500 steps of steepest
descent energy minimization (with heavy atom positions fixed) using the CFF91 force field
[62, 143].
P charges and atomic radii [209] were assigned for all amino acids. P radii
together with CFF91 charges were used for ligand atoms marked as HETATM in the PDB file,
with aliphatic CH hydrogen charges merged with the carbon charge to maintain compatibility
with the essential hydrogen scheme. Structures as well as atomic radii and charges were
translated from Insight format into the necessary form for the pKa calculation using a number
of specially developed programs.
2.2.2 pKa calculations
A PB titration model which had been previously applied to pKa calculations on HIV-1 PR
was used [227]. In this model, separate sets of partial charges for the neutral and ionized groups
are used [11]. The solute dielectric constant was taken to be 4. A dielectric constant of 20
is more reliable on average [12], but the results of the previous study suggest that the lower
dielectric constant is more accurate for the desolvated groups of interest in the HIV-1 PR
active site [227]. The dielectric constant of the bulk water phase was taken to be 80. The
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complex ligand model compound pKa
prmvt101 b MVT-101 N-ethylethylamine 10.0
1hbv SB203238 N-methyl-cyclohexylamine 10.3
1hpv VX-478 N,N-diethylsulfanilamide 1.8
1htf GR126045 2,5,5-trimethyl-1,3-thiazolidine-4-carboxamide 5.3
1htg GR137615 2,5,5-trimethyl-1,3-thiazolidine-4-carboxamide 5.3
1htg GR137615 2-ethylbenzimidazole 6.2
7hvp JG-365 N-ethyl-2-methylpyrrolidine 10.6
Table 2.3: Model compound pKas for ligand titrating groups
ionic strength was set to 150 mM for all calculations.
Additional procedures for dealing with the symmetry of the complex, and tautomerism
of the active site aspartates were followed [227]. Each of four possible neutral states for the
aspartate dyad (11 to 21 in Table 2.2) was considered in separate PB energy calculations,
and the resulting interaction matrices merged, with energies relative to a fully ionized refer-
ence state. Pairs of redundant interaction energies were replaced with single averaged values.
Simultaneous protonation of both oxygens of a single aspartate was prevented by inserting a
large artificial energy term (210 kJ mol−1) in the interaction matrix. In order to correct for
the statistical effect of counting two protonation sites per residue, the model compound pKa
is adjusted by − log10 2. Tautomeric forms of the basic secondary amine of MVT-101, the
thiazolidine groups of GR126045 and GR137615, the benzimidazole group of GR137615,
and the three carboxylate groups of Glu-Asp-Leu were also included in the calculations fol-
lowing an analogous procedure.
pKas were determined from the interaction matrices using the cluster method [83] or
a Monte Carlo simulation [14] where the cluster method proved unstable, or for the dyad
residues when the pKa fell outside the range of 0 to 15. Model pKas for the protein sidechains
were taken as: C-terminus 3.8; N-terminus 7.5; Asp 4.0; Glu 4.4; Arg 12.0; Lys 10.4; His
6.3; Tyr 9.6; Cys 8.3 [13]. Model pKas for ligand titratable groups were taken from literature
values obtained from the ACDlabs database [3] and are listed in Table 2.3. The pKa value for
the substituted thiazolidine is an empirical prediction made using the ACDlabs software [3].
Titration of the pyridyl groups of the inhibitors was not considered, as CFF91 parameters
for protonated pyridine were unavailable. As these groups bind in the S3/S3
′
pockets, no
significant interaction with the catalytic aspartyl dyad will take place.
The apparent pKa was defined as the pH at which the average protonation of a group
was 0.5. For the symmetric structures (1hvk and 1hvr; the interactions between A-74704 and
the aspartate residues in 9hvp were markedly asymmetric), where the aspartate residues are
indistinguishable, pKas for the aspartate dyad were defined as the pHs at which the sum of
the average protonation of the various tautomers was 0.5 and 1.5. Monte Carlo simulations
at the assay pHs were sampled to determine the relative occupation of the various tautomeric
states of the aspartate dyad, and tabulated following the scheme in Table 2.2. Proton linkage
energies were calculated using the general form of Equation 2.1.
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PDB code dyad D29 D30 D60 inhibitor
1a30 3.4, 15.8 <0 <0 1.4, 3.7 3.5, 1.8 10.1, 4.2, >15, >15
1aaq 15.3, 10.0 0.0, 1.2 0.0, 4.6 3.4, 3.0 6.0
1hbv 25.7, −8.2 1.0, <0 3.6, 2.6 4.4, 3.2 10.4
1hpv 6.8, 14.7 <0, <0 3.8, 2.8 0.4, 3.4 <0
1htf 6.8, 15.3 0.2, <0 2.4, 3.6 3.4, 4.4 <0
1htg 0.2, 23.2 2.0, 3.0 3.2, 3.2 4.2, 1.8 <0, <0
1hvi 9.4, 20.4 <0, <0 3.2, 3.6 0.0, 1.4 –
1hvj 25.4, 5.8 <0, <0 3.4, 2.6 1.6, 5.0 –
1hvk* 4.4, 22.7 <0, <0 3.6, 3.4 1.2, 1.8 –
1hvl 16.2, 9.0 <0, <0 3.4, 3.4 2.0, 1.2 –
1hvr* 1.2, 21.6 2.8, <0 3.6, 3.6 2.6, 4.8 –
prmvt101 22.7, −10.8 0.4, 0.6 3.2, 3.8 0.4, 1.4 8.0
5hvp 4.0, 15.4 <0, <0 4.4, 5.0 3.6, 0.2 6.2
7hvp 21.2, 4.2 <0, 0.4 5.0, 2.6 1.0, 4.8 <0
8hvp 25.3, 4.4 3.0, 1.0 0.4, 3.6 3.0, 4.0 5.4, 6.2
9hvp 15.7 −1.3 3.6, 2.2 2.4, 2.4 4.6, 4.2 –
Table 2.4: Calculated pKas for HIV-1 PR active site residues and ligand titratable groups.
Apparent pKas for the dyad are given in order of increasing value for the symmetric complexes
(marked with an *); otherwise values appear for the pairs of residues in the order as in the
PDB file.
2.3 Results and discussion
Calculated pKas are listed in Table 2.4. Results are shown for residues in the active site.
Large pKa shifts are predicted for all complexes, with at least one of the dyad pKas becoming
considerably more basic. This is a logical consequence of the desolvation of the dyad by the
inhibitor. The calculations show the second dyad group in 1hbv and prmvt101 as strongly
acidic, due to the presence of a positively charged ligand. Ligand titrating groups exhibit large
deviations from the model compound values in about half of the cases.
The predicted predominant dyad protonation states at the tabulated assay pH, presented in
Table 2.5, indicate that a number of different patterns of preferred protonation are possible. At
acidic pH, a fully deprotonated dyad is not expected to be observed for any of the complexes.
The commonly described state of a dyad singly protonated on one of the inner (Oδ1) oxygens
is fully populated for 1hbv, 1htg, 1hvk, 1hvr, prmvt101 and 9hvp, and predominant for 1hpv,
1hvj, 5hvp and 8hvp. Protonation of both outer oxygens dominates for 1aaq, 1htf, 1hvi,
and 1hvl. 1a30 and 7hvp show a preference for a single protonation of an outer oxygen.
Population of both singly and doubly protonated states for 1a30, 1htf, 1hvj, 5hvp and 8hvp
complicates further modelling studies, as the relative contribution of the two states to binding
energetics is unknown.
Similar calculations have been performed previously on the complexes 1hvr and prmvt101
by Trylska et al. [227]. The RMSD for the non-dyad residues between the present and
previously published results for 1hvr is 0.35 pKa units. The direction of the dyad pKa shifts
is consistent for prmvt101, though the magnitudes differ; the previous results predict less
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PDB code pH predominant protonation
1a30 4.3 02 0.67 22 0.26
1aaq 6.0 22 0.99
1hbv 6.0 10 1.00
1hpv 6.0 10 0.46 02 0.21 01 0.19
1htf 6.0 22 0.64 02 0.16 10 0.13
1htg 6.0 01 1.00
1hvi 6.2 22 1.00
1hvj 6.2 10 0.57 22 0.35
1hvk 6.2 10 0.56 01 0.38
1hvl 6.2 22 1.00
1hvr 5.5 10 0.56 01 0.43
prmvt101 6.6 10 1.00
5hvp 5.0 01 0.44 10 0.32 21 0.14
7hvp 6.5 20 0.96
8hvp 5.0 10 0.63 22 0.29
9hvp 4.7 10 1.00
Table 2.5: Predicted predominant protonation states (to 90th percentile) for the catalytic
aspartate dyad. The codes (bold type) refer to the scheme in Table 2.2. The most populated
states are given in rank order at the pH at which the Kis tabulated in Table 2.1 were assayed.
The modal assay pH of 6.0 was chosen for the calculations for 1hpv/VX-478.
extreme dyad pKas of −6.0 and 10.8. The direction of the shift for the secondary amine group
of MVT-101 is reversed, though both results indicate the group will be fully protonated at
assay pH. Comparison of the 1hvr dyad predictions is more puzzling. Trylska et al. predict
a strong shift to higher pKa for both dyad values, while the present calculations predict one
group will become more acidic.
NMR titration data suggest that the diprotonated state is favoured for the HIV-1 PR–
DMP323 complex [257], and it is expected that the analogue XK263 will behave very sim-
ilarly. However, the picture is confused by the absence of pH-dependence in the Ki of
DMP323, a result which Trylska et al. suggest brings into doubt the conclusion that the
NMR data indicate a diprotonated state [227]. The inconsistency between the calculations is
likely to be due to a difference in the modelling of the initial hydrogen-bonding pattern for
the various tautomers. Force field differences may also play a part, as the previous study used
Q charges for XK263, along with C22 bonded energy terms for minimization
of hydrogen positions, whereas CFF91 parameters were used in the present calculations. Dyad
pKas for the unliganded HIV-1 PR structures 3hvp [249] and 1hhp [215] (results not shown),
where only P charges were used and rotamer positions were not adjusted by hand, were
within 0.5 pKa units of the results of Trylska et al. in all cases.
Inconsistencies of this kind can be avoided by systematic optimization of the hydrogen-
bonding networks for the various tautomers, and consideration of possible changes in proton
positions in the various deprotonated states. These factors are ignored in the interests of ef-
ficiency in the Antosiewicz et al. method [11], resulting in a procedure with computational
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demands which scale linearly in the number of titrating groups. The procedure of Yang et
al. [258], as implemented by Nielsen [172] in W I [238], performs a full optimization
of proton positions for each interacting pair of titrating groups [103] in all four possible pro-
tonation states, giving a more robust procedure at the cost of quadratic computation time
requirements. This method was not used in the present study due to the difficulty of imple-
menting the additional forcefield parameters required for the peptidomimetic inhibitors within
W I.
The titration behaviour of the catalytic carboxylate groups in the complex of HIV-1 PR–
pepstatin has also been studied by NMR [214]. The pKa values for the dyad were measured as
< 2.5 and > 6.5, with the lower pKa thus considerable more acidic than the value predicted for
acetyl-pepstatin here (4.0) from 5hvp. Pepstatin binds to HIV-1 PR approximately 50 times
weaker than acetyl-pepstatin [74], and no structural data is available for the complex. The
discrepancy may therefore be due to small differences in binding mode. Both experiment and
calculation imply a strong preference for a monoprotonated dyad at the assay pH, although the
authors of the NMR study propose that one of the outer oxygens is protonated, in contrast
to the prediction in Table 2.5. An isothermal titration calorimetry study of the same system
measured a proton uptake of 0.4 protons at pH 6.5 [254]. This is consistent with bound pKa
values of 2.5 and 6.5, and is too low to be consistent with a shift of the more basic pKa to a
value as high as 15.4, if the free enzyme pKas of 3.5 and 5.5 can be considered accurate.
A subsequent ab initio molecular dynamics investigation of the active site protonation state
gives an alternative interpretation of the NMR data [182]. Protonation of one of the inner
oxygens was found to be more stable than protonation of one of the outer oxygens at the
picosecond time-scale investigated, a result also seen in the present calculations. However, a
doubly protonated state was calculated to give a better explanation of the observed chemical
shifts, suggesting that both dyad pKas become more basic in the complex. Such a shift, albeit
small for the more acidic group, is predicted as shown in Table 2.4. Table 2.5 shows a doubly
protonated state, corresponding to the favoured state from the Car-Parrinello molecular dy-
namics simulation, to be 14% populated at pH 5.0. A doubly protonated dyad would suggest
a larger proton uptake than 0.4 at pH 6.5, but other groups may show compensatory shifts.
Various other studies have made predictions of the catalytic dyad protonation state for
HIV-1 PR–inhibitor complexes without explicit reference to pH dependence. The crystal
structures were analysed with respect to energetic and/or geometric considerations, meaning
that predictions are relevant to the pH of crystallization. Rao et al. [187] predict a monopro-
tonated form for the complex 1hpv, with Asp25 neutral. This is in agreement with the most
populated protonation state in the present results. Geometric analysis of molecular dynamics
simulations of HIV-1 PR–MVT-101 has been used to predict the predominant protonation
state in two studies [81, 97]. The more recent of these (using the prmvt101 data, rather than
the earlier 4hvp structure) [81], nominated the 10 configuration in combination with a pro-
tonated ligand as most likely, again in agreement with the results in Table 2.5. Semiempirical
quantum chemical calculations on the 1hvi complex gave forms 20 and 01 as the lowest and
second lowest in energy [223], but did not consider doubly protonated forms, such as the
one found to be dominant in these results. A number of models have been proposed based
on different analyses of the 8hvp complex. The crystallographers give the 20 configuration
as preferred [114], based on hydrogen bonding analysis, while geometric analysis of an MD
simulation favoured a diprotonated form [97]. A later MD free energy simulation of ligand
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inhibitor pH1 K1i pH
2 K2i 1Gl ink expt 1Gl ink pred.
M M kJ mol−1 kJ mol−1
Glu-Asp-Leu 3.1 2.0 × 10−5 4.2 5.2 × 10−5 −2.4 −0.19
A-77003 4.7 8.4 × 10−11 6.2 1.2 × 10−11 4.8 13.
A-78791 4.7 3.5 × 10−11 6.2 4.0 × 10−11 5.4 9.6
A-76928 4.7 7.7 × 10−11 6.2 1.1 × 10−11 4.8 4.9
A-76889 4.7 1.0 × 10−9 6.2 1.1 × 10−10 5.4 13.
acetyl-pepstatin 4.7 2.0 × 10−8 5.0 3.5 × 10−8 −1.4 0.46
Table 2.6: Experimental and predicted proton linkage energies. Ki values measured at two
different pHs provide an experimental 1Gl ink. The prediction for the same pH change is
derived from the calculated pKa shifts of the catalytic aspartate residues. Experimental values
are from the references listed in Table 2.1.
stereoisomer preference suggested configuration 01 to be optimal [42]. None of these are in
agreement with the predicted dominant state of 10, but these calculations do suggest a sizable
contribution from the 22 form, which is predicted to be 29% populated.
Recalling the thermodynamic cycle in Figure 2.1 and Equation 2.1, the pH-dependence
of binding can be determined from the bound and free pKa values of the species. Experi-
mental results and calculations show that shifts in the active site aspartate pKas may make a
large contribution towards this pH-dependence, however, other groups may also be involved,
particularly ligand titratable groups. Accurate ab initio calculations of the pH-dependence are
not possible in this case, because of the accumulated error from the large number of groups to
be considered, and the difficulty of predicting pKas for small, flexible molecules, such as the
ligands described here. Prediction on the basis of experimental data alone is also unreliable in
this case, as the complete titration behaviour of free and bound states has not been adequately
characterised. Nonetheless, for some complexes, particularly those with non-ionizable lig-
ands, consideration of dyad shifts alone may be sufficient. Table 2.6 lists experimental and
calculated proton linkage energies for a number of complexes, with the calculations based on
experimental free pKa values for the dyad of 3.5 and 5.5, and bound values from Table 2.4.
Correspondence between measured and calculated linkage energies is poor, although, with
the exception of acetyl-pepstatin, the sign of the change is the same. Large ligand pKa shifts
are expected for both Glu-Asp-Leu and acetyl-pepstatin, so the neglect of these in the calcu-
lated energies is one possible explanation for the discrepancy. The calculated linkage energies
for the “A-7” series compounds appear to exhibit a trend towards exaggeration, which would
be consistent with the tendency of the calculations to overestimate pKa shifts in general. Fur-
thermore, the absence of pH-dependent binding in the case of the cyclic urea ligands, despite
experimental evidence for changes in dyad pKa (as noted above) underlines the uncertainties
of these comparisons; the same results are expected for the analogue XK263 included in this
study.
2.3.1 Accuracy of pKa predictions
Detailed comparisons with experimentally-determined pKas have pointed out systematic in-
accuracies in the approach followed here [12]. Additionally, unrealistically large shifts are
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sometimes predicted, which are clearly incompatible with normal protein pH stability pro-
files. An important source of error is the assumption of a single, rigid protein conformation.
Solvent-exposed groups can usually reorient freely, so a single modelled conformation is un-
likely to be representative. Changes in ionisation state may also be coupled to conformational
changes, and in general only one of these conformations will be observed in the crystal struc-
ture. Use of a high dielectric constant for the protein models the effect of the reorientation of
fixed dipoles to some extent, and this probably accounts for the greater average accuracy [12].
Explicit consideration of tautomerism, as done here, leads to a notable improvement in ac-
curacy, as does optimization of hydrogen bonding networks [173]. However, a more general
approach to conformational rearrangement, in which multiple hydroxyl rotamers are con-
sidered [8], does not result in radical further improvements. Sensitivity to the empirical
parameters of dielectric constant, partial charges, atomic radii, and small changes in atomic
coordinates is probably an important remaining source of problems. A scheme has been
developed in which the dielectric constant is adjusted according to the number of solvent-
exposed residues [55], and it has been suggested that a model in which the dielectric constant
varies continuously through space, with solvent exposed groups assigned a higher value than
desolvated groups, will improve matters [35]. This is put in perspective by recent results of un-
precedented accuracy achieved using a refinement of Tanford-Kirkwood theory [221], where
electrostatic effects were treated with less detail, while extensive side-chain repacking was sim-
ulated [98]. A true dynamic treatment of conformational change, for instance grand canonical
simulations of proton exchange, may eventually be needed to achieve good predictive accur-
acy, but such calculations will require further developments in force field parameterization and
be computationally intensive. Some initial work in this direction has begun to appear in the
last few years [16, 191].
Chapter 3
Electrostatic complementarity in HIV-1
PR–inhibitor complexes
3.1 Introduction
Accurate prediction of the affinity of a ligand for a protein receptor is difficult. Empirical
approaches (e.g. “scoring”) work quite well for certain classes of small, rigid ligand molecules,
but are unreliable for peptides. This is a notable failure, as many endogenous ligands are
peptides, and a number of peptidomimetic compounds are marketed as drugs, such as the
inhibitors of HIV protease. It is not clear whether this means that the process of molecular
recognition of peptide ligands is unusual, or if it only reflects a more general weakness of these
empirical models. The case of the HIV protease inhibitors is particularly interesting, as known
ligands range from peptides to highly hydrophobic peptidomimetics with reduced flexibility.
One sticking point in the analysis of the interactions in HIV-1 protease–inhibitor com-
plexes has been the role of electrostatic interactions. The aim of this study was to see if
careful modelling of electrostatics leads to a clearer picture of their contribution to affinity
and specificity in this system. A regression analysis was done to look at the importance of a
number of properties calculated from the crystal structures of the complexes, selected consid-
ering previous empirical studies of peptide ligands [18, 79, 161]. An measure of electrostatic
complementarity was also tested as an independent variable in the analysis.
3.1.1 Electrostatic complementarity
Electrostatic complementarity is a counterpart to the steric complementarity implied by the
lock-and-key model of receptor–ligand interaction. One possible definition is that the dispos-
ition of charge in the ligand should optimize the electrostatic interaction energy in the bound
complex, assuming that the bound geometry will be primarily determined by steric factors.
In concrete terms, electrostatic complementarity means that the number of salt bridges and
hydrogen bonds should be maximised, with positively charged groups in the receptor ap-
proaching negatively charged groups in the ligand and vice versa [169].
Steric complementarity is the most important factor in ligand–receptor binding. Hydro-
phobic interactions are closely allied, and are thought to be the factor driving association in
most cases [145]. In this scheme, electrostatic complementarity is important for determining
specificity, and does not make a large contribution to affinity [53,162]. The binding process is
a result of the balance of solvation-related factors. Electrostatic complementarity is a necessary,
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but not sufficient, condition for binding, as the interactions between polar groups and water
are close to optimal for the free ligand and receptor [53]. While this view is supported by
calculations showing that electrostatic interactions have a net destabilising effect for the major-
ity of complexes [204], modelling suggests that it is possible to design ligands with favourable
electrostatic binding energy for most receptors, without loss of specificity [44, 118, 119].
Molecular recognition has a physicochemical basis, but proteins and peptides have an evol-
utionary origin. This implies that the phenomenology of complementarity may have aspects
beyond those imposed by the physics of non-covalent interactions [222]. The differences in
shape complementarity between various classes of protein–protein interface are an example
of this [259], and suggest that the selection criteria of the immune system result in interfaces
which have different characteristics to those which have been shaped by a long process of nat-
ural selection. These differences can also relate to electrostatic interactions, as seen in studies
of catalytic antibodies [17].
Calculation of electrostatic energies for a given complex is straightforward, but simplified
models which capture the phenomenology of electrostatic complementarity are nonetheless
interesting. Visualisation of the molecular surface, colour-coded by electrostatic potential, al-
lows an intuitive assessment of complementarity [247]. Quantitative elaborations on this idea,
which reduces electrostatic complementarity from 3D to 2D, have been proposed for use
in docking and QSAR studies. Chau and Dean studied electrostatic complementarity in 34
ligand–receptor complexes, using the correlation coefficient of the ligand and receptor elec-
trostatic potentials at a set of points on the ligand Van der Waals surface, and found significant
correlation with negative slope in all but eight cases [40]. Superposition of independent ligand
and receptor electrostatic potentials is not physically meaningful, so the relationship between
these correlations and electrostatic complementarity is not rigorous. However, the method
was shown to give a good yardstick of complementarity for a number of model systems [41].
McCoy, Epa and Colman used an extension of Chau and Dean’s approach to investigate
electrostatic complementarity at protein/protein interfaces [146]. The most important refine-
ment they applied was to calculate the electrostatic potential using the Poisson-Boltzmann
equation and a semi-microscopic dielectric model, thereby including a model of solvation
effects. The authors found significant electrostatic complementarity at all twelve interfaces
studied. The magnitude of the correlation did not relate directly to the number of salt bridges
in the interface, and was not characteristic for a particular class of proteins.
There are some technical difficulties associated with the calculation of correlations between
electrostatic potentials. The choice of surface at which the correlation is calculated is rather
arbitrary. A common choice is the Connolly molecular surface [46] of the ligand or receptor,
though similarity calculations have been made using a volume in the interface, rather than
a surface [28]. Calculating the electrostatic potential at the molecular surface may lead to
inaccuracies, due to the quantization of the boundary between different dielectrics. Use of a
smooth transition between high and low dielectric constants alleviates this effect [39].
3.1.2 Master equation approaches
The mesoscopic continuum electrostatics model introduced in Chapter 2 can be used to es-
timate the free energies of solvation which are a large component of binding energies. Finite
difference Poisson-Boltzmann calculations can be applied to an electrostatic free energy cycle
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Figure 3.1: Electrostatic free energy cycle for rigid body association.
28 Electrostatic complementarity in HIV-1 PR–inhibitor complexes
for rigid body association of ligand and receptor, as depicted in Figure 3.1. Combined with
an estimate of the hydrophobic contribution to binding, calculated as a linear relationship
with buried surface area, this is the basis for a number of different master equation (or par-
titioning type) scoring approaches (e.g. [79, 176, 219]). The most successful applications of
this approach have been to the calculation of relative binding energies of complexes with
mutants [176, 202, 219], but absolute affinities of small molecule and peptide ligands can also
be predicted with moderate accuracy [79,121,183,195], usually with consideration of changes
of amino acid side chain entropy on binding.
Poisson-Boltzmann calculations to predict solvation and electrostatic interaction energies
are quite sensitive to the details of the microscopic charge model. Ambiguities in the place-
ment of protons, as discussed in the previous chapter, can lead to large energy differences,
and energies are quite sensitive to small changes in atomic coordinates when a low dielectric
constant is used for the protein interior [146]. As with pKa calculations, the appropriate choice
of dielectric constant is not obvious, as there is a tradeoff between physically realistic values
which give accurate energies for fully desolvated groups, and higher values which implicitly
compensate for electrostatic potential-induced conformational rearrangements [35]. A detailed
study of the dielectric relaxation associated with charge insertion in an enzyme active site has
highlighted the inconsistency between atom partial charges derived for molecular mechanics
simulations performed at a dielectric coefficient of one, and the requirements of continuum
models, which gave realistic results with a dielectric coefficient of 4–8 [208]. The P para-
meter set, optimized for a dielectric of two, goes some way to addressing this problem [209].
3.1.3 Problems scoring HIV PR inhibitors
HIV PR inhibitors have a number of characteristics which are likely to cause problems for
scoring algorithms. Foremost, they are extremely flexible molecules, with many freely rotating
bonds. The conformational free energy difference between the bound and free ligand may be
large, and is difficult to estimate. In addition, the interaction with the receptor appears to be
driven by the hydrophobic effect, a contentious phenomenon. Less obvious are the systematic
difficulties modelling the electrostatics of the HIV protease–inhibitor system. As discussed
in the previous chapter, proton linkage can make a large contribution to the free energy of
binding for many of these compounds, and the protonation state of the catalytic residues of
the enzyme is unusual. The combination of these uncertainties makes it hard to find out the
role of electrostatic complementarity in these interactions.
The general-purpose scoring functions of Bo¨hm [29] and Eldridge et al. [69] reproduce
the Ki values of HIV-1 PR ligand–receptor complexes badly. Moret et al. [161] found no
significant correlation between Bo¨hm-type scores and experimental affinities for a group of
fifteen complexes. No trend to under- or over-predict was noted, and the standard deviation
of the error in the predictions was 8.0 kJ mol−1. The Eldridge scoring function is a useful
benchmark, as a number of HIV-1 PR complexes were included in the training set, and a
detailed analysis of the relative performance with different classes of complex was provided.
The Eldridge aspartic protease training set (seventeen complexes) had a root-mean-square
residual of 8.6 kJ mol−1, but the ranking of affinities within the group is highly significant.
An interesting feature of the regressions is that the intercept and hydrogen-bond coefficient
specific to the aspartic protease set diverge noticeably from those of the other sets. The
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complex with MVT-101 (PDB code 4hvp) was an outlier in both the Moret and Eldridge
analyses.
Without a common test set, a direct comparison of the Bo¨hm and Eldridge scoring func-
tions is not possible. The one HIV-1 PR complex in the published Eldridge test set (A-74704,
PDB code 9hvp) is predicted badly, with an error of 14.22 kJ mol−1, and a separate test set of
ten endothiapepsin complexes has an RMS residual of 12.58 kJ mol−1, suggesting at least that
the Eldridge function is unlikely to be radically better than the Bo¨hm function. In the mean-
time, Bo¨hm has published an improved scoring function [30] which may do better predicting
HIV-1 PR affinities. The four HIV-1 PR complexes in the training set are fit well, with a
standard deviation of error of 2.2 kJ mol−1. Evaluation of the Moret HIV-1 PR dataset with
the new Bo¨hm scoring function (unpublished results) gave a highly significant correlation with
experimental affinities (r2 = 0.56, P = 0.002, Spearman ρ = 0.78, P = 0.002), and an RMS
residual of 6.5 kJ mol−1 using the standard scaling (LUDI Score = log10 Ki).
The V scoring function uses a larger set of descriptors than the Eldridge and
Bo¨hm functions, and includes a number of explicit energy terms [100]. HIV-1 PR–inhibitor
complexes make up 15 of the 51 structures in the training set. A test set of 13 modelled
HIV-1 PR–inhibitor complexes with a wide range of activities was included in the evaluation
of the parameterization, and was predicted with a RMS error of 5.0 kJ mol−1. The authors
qualify this impressive accuracy by noting that the training set is heavily biased towards this
type of complex. Performance on a test set of thermolysin inhibitors was considerably worse,
with an RMS error of 10.6 kJ mol−1, with the problem ascribed in part to the difficulty of
correctly dealing with a flexible ligand. Another noteworthy aspect of the scoring function
is the low weight assigned to the electrostatic interaction energy, which contributes only 3%
to the model. This might be seen as a result of inaccuracies in the treatment of electrostatic
interactions.
As expected, regression analysis restricted to HIV-1 PR complexes performs much better
than methods intended to be more broadly useful, presumably due to cancellation of errors
caused by the simplified form of the scoring function. For example, the extensive CoMFA
analysis of Waller et al. [178, 179, 242] achieves a RMS residual of 2.5 kJ mol−1. A more
surprising result is the relatively good performance of the empirical approach of Bardi et
al. [18]. Their predictions have a standard deviation of error of 4.6 kJ mol−1 using a master
equation parameterized from small compound data and protein databases. As with the equation
of Froloff et al. [79], opposing terms are present which cancel to a large degree. The more
convincing success of Bardi et al.’s approach may be due to the fact that the cancelling terms
are primarily dependent on the same solvent accessible surface area changes, so the errors will
be correlated.
None of these studies attempted to model the effects of protonation state on binding af-
finities and scoring parameters. Bardi et al. [18] considered all complexes to be equivalent
to pepstatin or KNI-272 in protonation state, and that the proton linkage effect would be
small at assay pH. In a 3D-QSAR study, Kulkarni and Kulkarni [125] carefully considered
the protonation state of the active site dyad, but a single model was then applied to all com-
plexes. The results in Chapter 2 and of Trylska et al. [227] suggest that these assumptions
are incorrect for some ligands. Eldridge et al. [69] mention variation in assay pH as a source
of error, implying that more detailed assay data are needed, and Oprea and Marshall make a
similar comment with specific reference to HIV-1 protease inhibitors [177]. Moret et al. [161]
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acknowledge that varying protonation states of the catalytic aspartate residues of HIV-1 PR
are important for scoring, and suggest pKa calculations as an aid to building more accurate
models. Bo¨hm [29, 30] and Waller et al. [242] do not address these issues.
The usefulness of a proton linkage correction term has been demonstrated for the calcula-
tion of the effects of point mutations on antibody–protein binding [202]. The change in free
energy of binding associated with ten independent point mutations in the protein (hen egg
white lysozyme) was predicted using a similar method to that of Froloff et al. [79]. Without
consideration of pKa shifts, the predictions were less accurate than the null hypothesis of zero
change in affinity between mutant and native. Consideration of predicted pKa shifts and the
associated proton linkage energies gave a model which was better than the null hypothesis,
despite the use of modelled structures for the mutants. In another example, Hansson and
A˚qvist [96] applied an assay pH-dependent correction to the benchmark data used in a mo-
lecular dynamics free energy simulation of HIV-1 PR inhibitors, improving the agreement
with simulation-derived results slightly.
3.2 Methods
The HIV-1 PR–inhibitor complex models used in the previous chapter were also used for
the present calculations. The protonation state of ligand titratable residues was fixed accord-
ing to the predicted predominant state at the pH of the assay conditions, following the pKa
calculations. For electrostatic energy calculations, the catalytic aspartate dyad was modelled as
doubly deprotonated to allow proton linkage energies to be considered consistently across all
complexes.
3.2.1 Poisson-Boltzmann calculations
Finite difference Poisson-Boltzmann calculations were used to determine electrostatic energies
and the electrostatic potential at the molecular surface. With the exception of the choice of
protein dielectric constant, the procedure followed was that described by McCoy, Epa and
Colman [146]. The program qdiffxs of DP 3.0 [85, 171] was used to solve the linearized
Poisson-Boltzmann equation, with the protein/ligand interior modelled with a dielectric of 8,
and the surrounding solvent with a dielectric of 80. The choice of a dielectric constant of 8 for
the protein was found to be optimal in a validation of a Poisson-Boltzmann master equation
scoring function [195]. The ionic strength was zero. P atomic radius parameters were
used [209] with CFF91 atomic partial charges [62, 143]. The molecular surface was defined
using a probe radius of 1.4 A˚. The finite difference calculation used a cubic grid of 2013
points, with a percentage grid fill of 90%, giving a grid resolution of approximately 3 A˚−1.
Debye-Hu¨ckel boundary conditions were used for the grid edges. When calculations were
performed with only ligand or receptor present, dummy atoms were used for the absent
species, to maintain the scale and orientation of the grid.
The electrostatic free energy change due to rigid body association, 1Gel, was calculated
using the free energy cycle in Figure 3.1. Following this scheme, the total electrostatic free
energy change is equal to the difference in energies between the complex and the sum of the
two isolated species. The electrostatic energy for each species is the sum of the energy needed
to bring the point charges together (the Coulombic energy) and the energy to transfer the
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Figure 3.2: McCoy et al. scheme for electrostatic complementarity calculations. The elec-
trostatic potential is calculated on the buried surface indicated by the thick line. The arrow
indicates that the correlation is calculated between potentials derived from the two systems.
The same procedure is used to calculate the correlation on the buried surface of the other
species, and the two coefficients are averaged.
charges from a low dielectric to a high dielectric medium (the solvation, or corrected reaction
field energy).
3.2.2 Proton linkage
Two measures of proton linkage were defined for each complex. As the weight of experi-
mental and theoretical evidence indicates that the aspartate dyad must be at least monopro-
tonated in the bound state, a linkage energy for this obligate protonation at the tabulated assay
pH was calculated using the following expression (derived from Equation 2.1).
1Gion = −RT log
10(pKa ) f −pH
1 + 10(pKa ) f −pH
The more basic of the experimental (pKa) f values of the dyad (5.5) was used for all complexes.
Consideration of the binding-related shift in the more acidic pKa of the dyad is more difficult,
as there is no clear indication of the relative binding energies of mono- and di-protonated
forms, and there appear to be characteristic differences between complexes. In addition, the
pKa shifts calculated in the previous chapter appear to be exaggerated or in conflict with
experimental data in some cases. Therefore a simple indicator variable, δion, defined as 1 if
the more acidic of the calculated pKas was less than the experimental free pKa of 3.5, and 0
otherwise, was chosen for further analysis.
3.2.3 Correlation of electrostatic potentials
A set of points on the molecular surfaces of the ligand and receptor, buried in the complex (the
“interface”), was calculated using the MS software [46], with a resolution of 4 A˚−2, using the
P atomic radii, and a probe radius of 1.4 A˚. The electrostatic potential at these points was
calculated separately for the ligand and receptor using qdiffxs, and a correlation coefficient was
calculated for each of the two buried surfaces. The Spearman rank correlation coefficient, ρ,
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PDB code 1Gexp 1Gel 1Gion δion EC 1A 1Anp 1Ap
kJ mol−1 kJ mol−1 kJ mol−1 A˚2 A˚2 A˚2
1a30 −24.45 30.61 0.455 1 0.550 −646.6 −398.0 −248.6
1aaq −47.91 60.75 11.9 0 0.071 −1078.9 −716.9 −362.0
1hbv −36.32 63.13 11.9 1 0.390 −1105.7 −839.9 −265.8
1hpv −52.61 49.36 11.9 0 0.364 −986.8 −736.2 −250.6
1htf −46.18 41.19 11.9 0 0.055 −822.5 −617.9 −204.6
1htg −55.21 44.75 11.9 1 0.283 −1136.7 −845.0 −291.7
1hvi −62.33 61.27 14.9 0 0.364 −1272.1 −953.6 −318.4
1hvj −65.05 55.35 14.9 0 0.176 −1266.8 −964.2 −302.6
1hvk −62.55 53.43 14.9 0 0.175 −1294.7 −969.8 −324.9
1hvl −56.79 61.53 14.9 0 0.354 −1276.3 −964.0 −312.3
1hvr −54.25 40.34 5.78 1 0.190 −1050.2 −859.6 −190.6
prmvt101 −34.85 31.11 21.7 1 0.417 −1285.7 −889.9 −395.7
5hvp −42.55 53.40 2.29 0 0.288 −1186.0 −832.9 −353.1
7hvp −54.88 65.12 19.9 0 0.356 −1338.5 −934.5 −404.0
8hvp −48.64 81.20 2.29 0 0.236 −1326.7 −880.0 −446.8
9hvp −47.62 42.13 1.22 1 0.331 −1206.9 −909.3 −297.6
Table 3.1: Free energy of binding derived from experimental Ki data and independent variables
for regression analysis.
was computed using the ctest library [106] of the R statistics program [111]. Each species was
considered partially desolvated by the volume of the other species in the complex, as shown in
Figure 3.2. The final score of electrostatic complementarity for each complex, EC, was equal
to minus the average of the two correlation coefficients, as defined by McCoy et al. [146].
3.2.4 Other parameters for regression
The molecular surface areas buried on binding, 1A, were measured using the MS program,
using the standard atomic radii and a probe radius of 1.4 A˚. Surface area was defined as
“non-polar” (1Anp) if it contacted carbon or CH hydrogen atoms, otherwise it was defined as
“polar” (1Ap). The resolutions (res) and R factors (R) of the structures, as noted in the Protein
Databank files, were also used as independent variables in the regression analysis, to indicate
possible effects of systematic shortcomings of the crystallographic refinement. A significant
correlation with resolution was noted in a previous study of HIV-1 PR complexes [161]. No
parameters related to Van der Waals interactions, intramolecular strain, or configurational free
energy were considered. Van der Waals interactions were considered subsumed by the surface
area terms, while the other parameters are either difficult to estimate, or approximately the
same for all compounds.
3.2.5 Regression analysis of ∆G
The 1Gexp values derived from the experimental Ki values from Table 2.1 of the previous
chapter, gave the values of the dependent variable in the regression analysis. Three multiple
3.3. Results 33
−70 −60 −50 −40 −30
−
10
0
10
20
Fitted values
R
es
id
u
al
s
prmvt101
1hvj
5hvp
1a30
1hvk
1hvr
Figure 3.3: Residuals for the regression equation 1Gexp = 0.321Gel + 0.041A − 13. The six
largest values are labelled.
linear regression analyses with stepwise removal of statistically insignificant terms were done
using the lm function in the statistics program R. The independent variables were (1) 1Gel,
1A, 1Gion, δion, res and R (giving a formulation similar to that of the master equation of
Novotny et al. [176]) (2) EC, 1A, 1Gion, δion, res and R, and (3) 1Anp, 1Ap, 1Gion, δion, res
and R.
3.3 Results
Three of the variables listed in Table 3.1 are significantly correlated with 1Gexp, 1A (r
2 =
0.32, P = 0.02), 1Anp (r2 = 0.48, P = 0.003), and δion (r2 = 0.29, P = 0.03). The correlation
with buried non-polar surface area (and by extension 1A, which is significantly covariant) is
to be expected given the hydrophobic nature of most of these ligands. Of the proton linkage
parameters, the only significant covariance is between δion and 1Gel (r
2 = 0.41, P = 0.01).
Stepwise multiple linear regression following scheme (1) failed to find a regression rela-
tionship where the influence of 1Gel was significant. The regression with the independent
variables 1Gel and 1A was significant (r
2 = 0.43, P = 0.03), but the coefficient of 1Gel did
not differ significantly from zero (P = 0.14). The residuals of this regression equation are plot-
ted in Figure 3.3. prmvt101 is clearly an outlier, as observed for MVT-101 in various previous
scoring studies. In this case, inclusion of the proton linkage parameters in the regression did
not help in explaining the unexpectedly poor affinity of this compound.
The analysis was repeated with prmvt101 excluded. A regression with the terms 1Gel,
1A, and 1Gion was found (r
2 = 0.74, P = 0.002) and is listed in Table 3.2. Removal of
34 Electrostatic complementarity in HIV-1 PR–inhibitor complexes
estimate std error t value P(> |t |)
(intercept) −10.32 9.6 −1.1 0.31
1Gel 0.38 0.19 2.0 0.07
1Gion −0.79 0.29 −2.7 0.003
1A 0.05 0.01 −3.7 0.02
Table 3.2: Best regression following scheme (1) with prmvt101 excluded. s = 6.1, multiple
r2 = 0.74, F3,11 = 10.4 (P = 0.002).
estimate std error t value P(> |t |)
(intercept) −21.48 8.9 −2.4 0.04
1Gel 0.51 0.16 3.1 0.01
1Gion −0.53 0.23 −2.3 0.05
1A 0.05 0.01 −4.6 0.001
δion 9.49 3.36 2.8 0.02
Table 3.3: Best regression following scheme (1) with prmvt101 excluded, and 1G ion and δion
corrected for 1hvr. s = 5.1, multiple r2 = 0.83, F4,10 = 12.48 (P = 0.0007).
the 1Gion term results in a large decrease in the significance of the coefficient of 1Gel (from
P = 0.07 to P = 0.17), suggesting that the proton linkage energy is fulfilling its role as as a
correction to the electrostatic energy term. No significant regression equation including both
the 1Gel and δion terms was found.
As discussed in the previous chapter, the binding of the cyclic urea inhibitor DMP323 to
HIV-1 PR is not pH dependent. The close analogue XK263 is expected to exhibit similar
behaviour, which means that the proton linkage correction term 1Gion should be zero for the
complex 1hvr, in contrast to the calculated value of 6 kJ mol−1. The calculated pKa shifts are
also at odds with previously published experimental work and calculations. 1G ion and δion
were both changed to zero to be consistent with this information. A regression equation with
the terms 1Gel, 1A, 1Gion, and δion was the result (r
2 = 0.83, P = 0.0007), and is given in
full in Table 3.3, with residuals plotted in Figure 3.4. Exclusion of the 1G ion, and δion terms
reduces the r2 to 0.57 and the significance of the 1Gel coefficient to P = 0.17.
Regressions involving EC following scheme (2) did not yield any significant relationships.
With the corrections to the 1hvr parameters, scheme (3) resulted in an equation with the terms
1Anp, 1Ap, and δion (r
2 = 0.77, P = 0.0004), shown in Table 3.4. The significance of the
estimate std error t value P(> |t |)
(intercept) −25.24 9.7 −2.6 0.02
1Anp 0.05 0.01 −4.4 0.0008
1Ap −0.05 0.02 1.9 0.08
δion 10.94 3.3 3.3 0.006
Table 3.4: Best regression following scheme (3) with 1Gion and δion corrected for 1hvr.
s = 5.9, multiple r2 = 0.77, F3,12 = 13.21 (P = 0.0004).
3.4. Discussion 35
−70 −60 −50 −40 −30 −20
−
5
0
5
10
Fitted values
R
es
id
u
al
s
5hvp
7hvp
1htg
8hvp
Figure 3.4: Residuals for the regression equation in Table 3.3. The four largest values are
labelled.
1Ap term is marginal.
3.4 Discussion
The combination of electrostatic energy, buried surface area, and proton-linkage correction
terms gives a regression equation with reasonable parameters for a data set spanning a wide
range of activities and a number of structural classes. These results indicate that the continuum
electrostatics approximation can be applied to sets of hydrophobic, peptidomimetic ligands.
The difference in correlation coefficient between the regression including 1Anp alone (r
2 =
0.48) and the regression including 1Gel (r
2 = 0.83) indicates the contribution of electrostatic
effects to binding. Inclusion of proton linkage in the analysis is necessary to give reasonable
accuracy and statistically significant parameters. Both information on assay pH conditions and
ligand-induced pKa shifts contribute usefully to the model.
The electrostatic complementarity measure defined by McCoy et al. [146] did not prove
useful for scoring in this context. This parameter is correlated with the Coulombic interaction
energy in the complex, and does not fully encapsulate the information about the desolva-
tion penalties which are so important to the overall magnitude of the electrostatic interaction
energy. EC values are fairly low for this data set, with 1a30 having the highest value, re-
flecting the polar character of the ligand EDL. This parameter is probably more suited for
analysis of protein–protein interfaces, where more variation in electrostatic complementarity
is encountered, and for classification rather than quantitative applications.
The surface-area-based model of scheme (3) gives a reasonable regression. The dominance
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of hydrophobic interactions means that the buried non-polar surface area alone explains close
to half the variation in activity between ligands. The linkage term δion makes a significant
contribution, but the polar surface area appears to be somewhat unreliable as an additional
parameter.
There is no ready explanation for the exceptional nature of prmvt101. The discovery
of errors in the refinement of the previously deposited coordinates, 4hvp [155] provides an
obvious reason why this complex was repeatedly found to be an outlier in earlier studies.
However, other factors may be significant, including the low affinity of the compound, the
presence of alternative binding modes in the crystal structure, or the relatively high pH (6.6) at
which the Ki was measured. The interaction of the cationic secondary amine of the inhibitor
with the catalytic aspartic acid groups, causing large pKa shifts, may also be an important factor.
Similar interactions are present in the complex 1hbv with SB203238, which was also found to
be an outlier in the scoring study of Moret et al. [161]
3.4.1 Comparison with other work
The coefficients derived in the regression equations are quite stable and agree reasonably well
with physical intuition. The coefficient of 1Gel is steady at about 0.4, consistent with the
results of Novotny et al. [176] (although a different dielectric constant was used in this study),
and not far from the ideal value of one. Similarly, the coefficient of the proton linkage
term 1Gion at approximately −0.5 is commensurate with 1Gel. The buried surface area
coefficient, at close to 50 J A˚−2, is only about a third as large as that found to be optimal
in other studies [176, 195], although this may be in part an artefact of differences in the
calculation protocol. It is difficult to give a physical interpretation of the coefficient of δ ion
of ∼ 10 kJ mol−1. However, for comparison, this is approximately the difference in proton
linkage energies at pH 6.0 between that for a pKa of ≤ 3.5 and 6.5 at pH 6.0.
A regression approach allows a more accurate fit of the data at a possible cost to the
transferability of the equations derived. The master equation approach of Schapira et al.
[195] uses a similar electrostatic energy term to the one used here, together with extensive
conformational sampling, and consideration of entropy. The results for a test set of 13 HIV-
1 PR–inhibitor complexes (seven of which are included in the data set of this chapter) had
an RMSD from experiment of 9.8 kJ mol−1, considerably worse than achieved here, even
though the dielectric constant, surface area coefficient and an additive correction constant (i.e.
the intercept) were optimized for the data set in question. To allow the present results to
be roughly compared with those of Schapira et al., the unscaled 1Gel term was subtracted
from 1Gexp and the residual fit to 1A. This yielded a residual standard error of 9.4 kJ mol
−1
(prmvt101 excluded), a comparable performance, even though no entropy term was used.
Correction with the unscaled 1Gion decreased the error to 8.1 kJ mol
−1, and inclusion of δion
in the regression gave a further improvement to 6.9 kJ mol−1.
In the absence of data on an identical, independent test set, the work here cannot be
compared closely with other published studies. The accuracy falls in the range achieved by
the better general-purpose scoring functions, such as those of Bo¨hm [30] and Bardi et al. [18],
which is acceptable considering the small number of parameters included in the regressions.
However, the regression relationship is probably not very robust, as the necessity of remov-
ing prmvt101 from the data set suggests. While the results show that improvement in the
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calculation of electrostatic interaction energies is possible for the HIV-1 PR–inhibitor system,
increased reliability for flexible ligands, and overall accuracy to the level of less than 6 kJ mol−1
appears to remain beyond the reach of general purpose regression and master equation scoring
functions.
3.4.2 Alternative approaches
There are a number of alternative approaches to the semi-microscopic Poisson-Boltzmann
model for the calculation of solvation and interaction energies. Free energy calculations using
Molecular Dynamics or Monte Carlo simulations are the most physically realistic methods,
but these are often prohibitively expensive due to slow convergence (see the introduction to
Chapter 4 for further discussion). Results from free energy calculations generally agree with
experimental measurements (e.g. for relative binding energies of the stereoisomers of an HIV-
1 PR inhibitor [187]), but statistical analysis of the accuracy has been hindered by the difficulty
of generating large, consistent data sets. It is also difficult to decompose free energy results
into entropy and enthalpy components which can be compared with experimental results or
empirical predictions. An additional problem is that results may be force field dependent, as
seen in simulations with small solute molecules [137]. Current surface-area-based models of
hydrophobic binding are unlikely to be as accurate as explicit solvent free energy simulations,
though the semi-empirical nature of the charge and radius parameterization means that good
results are possible at least with small solutes [209], and as shown by Bardi et al. are competitive
with general purpose scoring functions [18].
Linear Interaction Energy (LIE) calculations, an extension of linear response theory, com-
bine features of free energy calculations and empirical approaches [15]. These simulations
are considerably faster than free energy calculations, so a statistical comparison with empirical
scoring functions is plausible. The performance of LIE and related approaches in predicting
small molecule solvation energies has been extensively tested, and was shown to be compet-
itive with empirical, fragment-based methods for predicting log P(octanol/water) [68]. LIE
uses one to three empirical parameters to predict 1G values, and these do not appear to be
transferable from one protein–ligand system to another [240], making comparisons more com-
plex. The accuracy of an LIE analysis of HIV-1 PR binding affinities [201] was comparable to
regression approaches specialized for this receptor, although an earlier, less sophisticated study
of three inhibitors gave much larger errors [96]. The advantage of LIE over conventional free
energy calculations was not apparent, as an explicitly calculated entropy term (which needed
a long simulation to converge) was included in the later study.
Studies of knowledge-based potentials, developed for protein folding applications, applied
to scoring, indicate that this approach is competitive with other scoring methods. One of the
first applications was to the system of HIV-1 PR and inhibitors, with one important motiv-
ation to develop a method which could bypass the need to consider protonation explicitly.
Verkhivker et al. [231] found that the combination of an atomic contact score with an empir-
ical solvation scale was able to differentiate between MVT-101 and JG-365, inhibitors with
similar binding modes but differing considerably in affinity. Wallqvist et al. [243] followed
a very similar approach, but parameterized their potential using a diverse set of high resolu-
tion protein crystal complexes, rather than HIV-1 PR complexes alone. This more general
approach gave a reversed ranking for the affinities of MVT-101 and JG-365, but the overall
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performance was nonetheless quite good, with a mean absolute error of ≈ 6 kJ mol−1.
More refined methods of analysing molecular electrostatic potentials, or electric fields,
may allow better qualitative and quantitative study of electrostatic complementarity. Use of
a correlation coefficient calculation is intuitively appealing, but the details are fairly arbitrary.
It may be possible to produce more predictive results by using a different surface, or even a
volume, to define corresponding points. Other measures of complementarity than correlation
coefficients may prove to be better; dipole and higher moments may also make an important
contribution. It has also been suggested that the magnitude of the electric field vector at
the molecular surface may act as a simple hydrophobicity index, allowing another type of
correlation to be assessed [169].
3.4.3 Flexibility
Flexibility of the ligand and receptor is notable in its absence from this analysis. An impli-
cit treatment, as with the use of an increased dielectric constant, will be inadequate when
a substantial change in conformational behaviour occurs on binding. Molecular mechanics
calculations have suggested that bound conformations are relatively low in potential energy
compared to free [33], but the contribution to affinity might still be significant. In such cases,
a predominant states model of conformational changes may be useful [84]. Whether this ap-
proach or a more complete one is chosen, conformational analysis of the ligand (and possibly
the receptor) will be required.
For very flexible ligands, such as peptides, consideration of binding-related entropy
changes is important. A static predominant states model does not help to achieve this. Entropy
estimates can be calculated from a harmonic approximation to the potential energy surface,
or using the “mining minima” method of Gilson and Head [99]. However, when there are
many shallow minima, explicit sampling of the equilibrium ensemble is necessary. Sophist-
icated Monte Carlo techniques, such as configurational bias Monte Carlo, hold promise for
doing this more efficiently.
Chapter 4
CBMC: implementation
4.1 Introduction
Empirical analysis of molecular recognition in terms of static complementarity has some sub-
stantial shortcomings when applied to drug design. The omission of a good account of solva-
tion effects, or more generally, entropy contributions, results in a poor ability to predict bind-
ing affinity for many systems. There have been notable successes in the more limited question
of docking (prediction of the preferred configuration of the ligand–receptor complex), but
not with highly flexible ligands such as peptides. When empirical models are an inadequate
description of the recognition process, an alternative approach is computer simulation with a
detailed physical representation of the relevant microscopic system, using the theory of statist-
ical mechanics to predict macroscopic properties.
Many properties of chemical systems can be conveniently predicted by computer simu-
lation. Molecular dynamics (MD) [7] is an elegant approach to many problems [77], which
allows the simple calculation of many thermodynamic properties, as well as dynamic ones such
as diffusion coefficients. Equilibrium conformations observed in MD simulations can indicate
possible modes for molecular recognition, as well as providing an explanation of results from
NMR, circular dichroism or other spectroscopic experiments. Theoretically exact methods
using MD also exist to calculate free energy changes such as equilibrium (dis)association con-
stants, with an accuracy limited only by the realism of the empirical potential function.
Nevertheless, in many cases MD is unable to reproduce the behaviour of macroscopic,
experimental systems, due to the extremely limited size and time scales which can be feasibly
simulated [91]. Equilibration of protein folding, for example, is on a time scale of milliseconds
for hen egg white lysozyme [186], while simulations of a single, solvated protein molecule have
only recently reached the order of one microsecond in duration [66]. The long diffusion times
or low successful encounter rates of other processes are a similar impediment. Simulations of
diffusion controlled binding processes require time scales of about 100 ns [239], and orders
of magnitude more simulation time will be needed where the complex forms with more
difficulty.
Potential energy barriers (for instance, the formation of a transition state) are crossed
only slowly in MD simulations at constant energy (micro-canonical ensemble; constant-
NVE) or constant temperature (canonical ensemble; constant-NVT). In order to acceler-
ate barrier crossing, various non-physical modifications to the potential can be used, short-
circuiting impractically slow convergence of simulations which involve an activated process.
Examples include umbrella sampling [225], and generalised ensemble techniques (such as en-
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tropy sampling) [134]. Monte Carlo (MC) [152] simulations do not reproduce natural dy-
namics, so they may equilibrate more quickly than MD [200], though they also can become
trapped in local minima on the potential energy surface. Many of the schemes used to improve
the sampling of MD can also be applied to MC, though with MC there is also the freedom to
use special, non-physical trial moves to this end.
Molecular dynamics has been the preferred method in most computer simulations of pro-
teins and peptides. Monte Carlo simulations are of comparable efficiency for small solutes [116]
but can become extremely inefficient for chain molecules in solution. On the other hand,
even in well-thought-out MD simulations it is often clear that convergence of the properties
of interest is not reached, despite complicated sampling schemes. With increasing computer
speed, longer simulation times mitigate this problem, but given the many orders of magnitude
to be bridged, improved algorithms are desirable. For example, a simulation of the binding
of a peptide ligand to ribonuclease S, to predict the effect of a single residue mutation [174],
gave unacceptably large statistical errors and failed to converge despite a total simulation time
of more than 1 ns, and the use of additional experimental data to guide the simulation.
In part as a result of these limitations, computer simulations for medicinal chemistry ap-
plications have not achieved the successes seen in other areas of chemical physics. The only
widespread use of free energy simulations is to predict the effects of small changes in lig-
and molecular structure on the association equilibrium (i.e. by thermodynamic integration
or overlapping histogram/free energy perturbation methods [251]). Efficient simulation al-
gorithms are needed to make more difficult problems tractable, with the ultimate aim of
enabling the direct simulation of ligand–receptor association (e.g. by a grand canonical en-
semble simulation). The aim in this chapter was to implement the configurational bias Monte
Carlo (CBMC) algorithm, a method which can greatly improve the efficiency of simulations
of flexible polymer chains, for peptides, with an eye for new applications in simulations of
ligand–receptor interactions.
A number of force fields exist which were designed for MD simulations of proteins, and
which describe the energetics of peptide conformations quite well [23]. Simulation results
are nonetheless largely force field-dependent [216], so evaluation and comparison is far easier
with the use of a widely-used potential. In any case, determining the parameters for a protein
force field is difficult and labour-intensive. In this chapter the implementation of a CBMC
algorithm using the C22 all-atom protein force field [36, 141] is described. Correct
use of this potential requires specific attention to the details of the CBMC algorithm, and
systematic validation that it is consistent with existing implementations. As the intention is
to use CBMC for conformational sampling and free energy simulations, the reproduction of
conformational probability distributions was chosen as the criterion for validation.
4.1.1 Configurational bias Monte Carlo
The Monte Carlo importance sampling algorithm introduced by Metropolis et al. [152] is
an efficient method for determining ensemble averages of observable, equilibrium properties,
requiring only the ability to calculate the potential energy for a given configuration. Successive
states of system follow in a Markov chain, with transition from the old state to the new (a step
or move) determined in two phases. First, a new, trial, configuration is generated; in the
Metropolis scheme this is generated by adding an unbiased random displacement to one of
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the particles in the system. Second, an acceptance rule determines if the next state in the
Markov chain will be the new configuration, or a repeat of the old configuration. The rule in
the Metropolis scheme gives an acceptance probability proportional to the ratio of Boltzmann
factors (e−U /kB T ) of the new and old configurations. If ergodicity is assumed (that is, all states
which contribute to the ensemble are mutually accessible), then it is straightforward to prove
that Metropolis MC samples a canonical ensemble.
Efficiency of the MC scheme is determined by the rate at which successive states explore
phase space (the set of configurations which contribute to the ensemble). This is bounded
by the size of the change in configuration generated by the trial move, as well as by the
probability that the trial move will be accepted (the acceptance ratio). As these two quantities
are to a certain extent complementary, maximum efficiency is achieved by balancing them;
for Metropolis MC this is generally achieved with an acceptance ratio of about 50%. As with
MD, phase space bottlenecks, such as a simple potential energy barrier, impede convergence
by trapping the system for many steps. For simulations at high density, most MC schemes
suffer from more obvious forms of trapping, marked by an extreme decrease in the acceptance
ratio.
Many MC schemes exist which exploit a biased or non-physical generation of trial moves
to improve sampling efficiency. Rosenbluth and Rosenbluth [193] introduced a biased
sampling method for polymers, where conformations of idealised chain molecules on a lat-
tice were generated using a self-avoiding random walk, with ensemble averages calculated
using a specially weighted average. Configurational bias Monte Carlo (CBMC) [76, 180, 207]
builds on the principle of Rosenbluth sampling, using a Rosenbluth-like rule for generating
trial moves together with an acceptance rule which results in a canonical ensemble.
Smit et al. [211, 212] have used CBMC in simulations of phase equilibria of alkanes, and
simulations of adsorption isotherms of alkanes in zeolites, where extremely slow equilibration
times (laboratory experiments may take weeks to equilibrate [217]) rule out the use of a na-
ive MD approach. Grand canonical MC (constant-µVT) is effective for short alkanes, but
as chain length increases, the acceptance of trial moves approaches zero. CBMC avoids this
problem by the biased generation of trial configurations which have low energy external (in-
teractions between chains or with the zeolite) and internal (e.g. bond stretching and bending)
interactions.
The first, simple, lattice formulation of CBMC has been extended with time to ever
more complex continuum potentials. The CBMC literature on alkanes uses primarily united-
atom potentials, with bond stretching, bending, and torsions as bonded terms. Treatment
of branched molecules and multiple interdependent energy terms in the bonded potential,
requires an elaboration of the basic continuum CBMC algorithm. Realistic simulations of
molecules more complex than alkanes — peptides for example — involve the use of a more
complicated force field, and these additions, such as the use of multiple torsions, give need for
further revisions to the CBMC scheme.
4.1.2 CBMC for polypeptides
CBMC has been applied with some success to the conformational analysis of simple poly-
peptide models in a vacuum. Schofield and Ratner [199] used a C-like potential and
a variety of non-physical-sampling Monte Carlo techniques, including CBMC of the pep-
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tide backbone dihedral angles, biased according to the preferred regions of the Ramachandran
map. The combination of these techniques yielded promising results, with good convergence
for pentaglycine. The authors state that limiting the use of CBMC to the equilibration of
backbone dihedrals is more efficient than using CBMC to generate the entire conformation;
however, this approach precludes direct calculation of the excess chemical potential from the
Rosenbluth factor (as well as grand canonical and Gibbs ensemble simulations), and makes sim-
ulations in the face of strong inter-molecular interactions, such as binding, impractical. The
multiple Markov chain method (also known as parallel tempering) [82] is suggested as a route
to further improvement upon the non-Boltzmann entropy sampling MC scheme employed.
Deem and coworkers describe a more conventional application of CBMC to peptides,
with particular attention to the efficient simulation of cyclic peptides [54, 252, 253]. An A-
-like potential was used, with the added simplification of fixed bond lengths and angles,
and rotation only possible around σ-bonds, reducing the potential to only torsion and non-
bonded terms. Equilibration of systems with constrained backbones was assisted by the use
of rebridging/concerted rotation. Further improvements in efficiency were achieved with
parallel tempering, and the addition of “look-ahead”, inspired by the Meirovitch scanning
method [148–150]. As backbone and sidechains are equilibrated in separate CBMC moves,
insertion of a complete chain into the simulation in one move is impossible, resulting in the
same limitations as the method described by Schofield and Ratner [199]. The radical simpli-
fication of the forcefield speeds up the simulations considerably, but as angle constraints cause
significant changes in the behaviour of the force field [92], results cannot be compared directly
with published results using A, and are likely to be less realistic.
A number of other biased-sampling techniques for peptides have been described. Garel
and collaborators have developed a recursive, static MC scheme for conformation analysis
[20], using a potential similar to Deem, with biasing of backbone torsions according to the
Ramachandran plot. A related technique is the pruned-enriched Rosenbluth method [75],
although it has only been applied to lattice protein models. Derreumaux has applied diffusion
process-controlled MC to a simplified peptide model, with biased exploration of the backbone
torsion modes [56,57], a procedure designed for global search for energy minima. The biased
probability Monte Carlo/optimal-bias Monte Carlo minimization procedure of Abagyan and
Totrov [1, 2] has similar features, with more extensive use of torsional biasing from empirical
distributions.
4.2 Methods
4.2.1 CBMC
CBMC generates conformations from a canonical ensemble efficiently, by avoiding high en-
ergy internal and external interactions. Instead of random changes to the coordinates of a
molecule, molecules are “grown”, atom by atom, at each step choosing a configuration with
a bias towards low energies (Figure 4.1). The effect of this bias is then removed by a specially
constructed MC acceptance rule. The biased selection is done by generating a number of
alternative positions for each new atom, and then choosing one randomly with a probability
proportional to the Boltzmann factor of the associated energy.
A simple continuum CBMC algorithm concerns an unbranched chain of l linear segments.
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Figure 4.1: Scheme for biased growth of a new polymer chain. The k trial bond vectors,
b1, . . . ,bk, are illustrated, one of which will be selected to make bond i from atom i to atom
i + 1. bk will be chosen with a low probability, as it has a high potential energy.
Reproducing the formulation of the algorithm presented in [77], the potential energy is di-
vided into U bond, the sum of the bonded terms in the force field, and U ext, accounting for
all interactions with other molecules, as well as all non-bonded intramolecular interactions.
To perform a Monte Carlo move, both a trial (new) conformation and the old conformation
need to be considered. For the new conformation, assuming that i − 1 bonds along the chain
have already been grown, bond i is added as follows:
1. Generate k trial bond vectors, chosen from a Boltzmann distribution according to the
bonded interactions with atom i (ubondi ), giving the set {b}k = {b1, . . . ,bk}, where the
probability of generating bond vector segment b is therefore
pbondi (b)db =
exp
[
−βubondi (b)
]
db∫
db exp
[
−βubondi (b)
]
with β = 1
kBT
2. One of the k bond vectors is selected with a probability
pexti (bn ) =
exp
[−βuexti (bn )]
wexti (new)
defining
wexti (new) =
k∑
j=1
exp
[−βuexti (b j )]
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This becomes the ith bond of the trial conformation
Once the entire molecule has been grown, the Rosenbluth factor can be calculated:
W ext(new) =
l∏
i=1
wexti (new)
where the Rosenbluth factor of the first atom of the chain is
wext1 (new) = k exp
[−βuext1 (r1 )]
with r1 the position of the first atom.
A similar procedure is used to calculate the Rosenbluth factor of the old configuration.
1. A molecule is selected at random and designated “old”.
2. The Rosenbluth weight of the first atom in old is calculated
wext1 (old) = k exp
[−βuext1 (old)]
3. The Rosenbluth weights of the remaining l − 1 bonds are then calculated. For a given
segment i the procedure is analogous to that for the new configuration.
k−1 trial bond vectors are generated, which together with the actual bond from i−1 to
i, make a set of k bonds, {bo,b′2 . . . ,b′k}, from which the external Rosenbluth weight
of the segment can be calculated:
wexti (old) =
k∑
j=1
exp
[−βuexti (b j )]
4. The Rosenbluth factor of the old conformation is then
W ext(old) =
l∏
i=1
wexti (old)
Once the new configuration has been generated, and the old and new Rosenbluth factors
have been calculated, the Monte Carlo move is accepted with a probability of
acc(old→ new) = min [1,W ext(new)/W ext(old)]
A proof that the algorithm samples a Boltzmann distribution can be found in [77].
4.2.2 BIGMAC
The program B [233,234] was developed in tandem with a united-atom force field for
alkanes and zeolites, optimised to reproduce thermochemical properties such as adsorption iso-
therms. Bond stretching and bending are modelled by harmonic potentials (an earlier version
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of the software used fixed bond lengths), and torsions by a four term power series expansion
on cos φ. Non-bonded interactions consist of a Lennard-Jones potential, and, optionally, a
Coulombic term with Ewald correction [72, 135, 136].
Various simulation types in a number of different ensembles are implemented, allowing
the calculation of heats of adsorption, Henry coefficients, adsorption isotherms, vapour-liquid
coexistence curves and so forth. Most importantly, a number of types of CBMC moves can
be used, which in the simplest case give efficient simulations of long-chain alkanes in the
canonical ensemble.
B uses a number of efficiency optimisations made possible by the freedom of choice
in which the force field potential is partitioned between the biased growth steps and the ac-
ceptance rule within the CBMC algorithm. Evaluation of bonded potentials is cheap, re-
quiring a constant number of operations (O(1)) per grown atom, so repeated evaluation of
these to select favourable internal coordinates is not costly. On the other hand, long-range,
non-bonded potential evaluation is much more expensive. The dual-cutoff algorithm [235] is
an optimisation which moves evaluation of the most expensive terms to the acceptance rule,
so they only need to be calculated once per grown chain .
B implements a number of parallel algorithms, giving faster execution on multi-
processor computer systems; a parallel CBMC algorithm [71] is used. The parallel code is
written using the portable MPI parallel programming interface [151], so it can easily be run
on heterogeneous groups of workstations, or large clusters of low-cost PCs
4.2.3 CHARMM22 potential
The C computer program for macromolecular simulation, together with its empirical
potential parameter sets, has been under ongoing development since the mid-1970s. There has
been considerable cross-fertilisation between different protein force fields, and as a result, the
A, OPLS, C and G empirical energy functions have a lot in common.
The C22 parameter set, dating from 1992, is the result of a number of rounds of
improvement, and considerable effort in deriving parameters suitable for a variety of different
types of condensed-phase simulations.
The C22 empirical energy function has the form
Vbonded =
∑
bonds
kb(b − b0)2 +
∑
angles
kθ (θ − θ0)2 +
∑
UB
kUB(S − S0)2
+
∑
impropers
kφ (φ − φ0)2 +
∑
torsions
kχn [1 + cos(nχ − δn )]
Vnonbonded =
∑
i< j
²i j

 rmini j
ri j
12 −
 rmini j
ri j
6
 + qiq j
²1ri j

where the sums are over bonded atoms as indicated in Figure 4.2. The bond, angle, Urey-
Bradley, dihedral angle, and improper dihedral angle force constants are kb, kθ , kUB, kφ , and
kχn respectively; b, θ , S, φ, and χ are bond length, bond angle, Urey-Bradley 1-3 distance, im-
proper torsion angle, and torsion (dihedral) angle. A single torsion angle may have coefficients
kχn for multiple Fourier terms n = 1, 2, 3, 4, 6, each with a phase offset of δn (in practice always
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Figure 4.2: Bonded energy terms in the C22 potential
0 or 180 ˚ ). All possible bond angle and dihedral angle terms are present, whereas improper
torsions and Urey-Bradley terms are only defined for particular groups where necessary.
The non-bonded potential consists of a Lennard-Jones and a Coulomb term. Lennard-
Jones terms are described by a well-depth, ²i j , and a distance at the Lennard-Jones minimum,
rmini j , which between pairs of different atom types are combined using the Lorentz-Berthelodt
rules (geometric mean of ²i j and arithmetic mean of r
min
i j ). The Coulomb interaction is defined
by the charges on the two atoms, qi and q j , at a fixed (vacuum) effective dielectric constant
²1. In both terms ri j is the distance between atoms i and j. Non-bonded interactions are
over all possible pairs of atoms in the system, with the exclusions of directly bonded atoms,
and atoms with two bonds separation. In some cases, a scaled-down well-depth is used for
Lennard-Jones interactions when atoms are separated by three bonds (1-4 interactions).
The C22 functional form differs from the B force field in a number of
important ways: the use of a harmonic angle potential instead of a harmonic cosine potential;
use of improper dihedral terms; use of Urey-Bradley terms; use of a Fourier torsion term
instead of power series; use of special coefficients for the non-bonded interactions of 1-4
bonded atoms. The total number of parameters is considerably larger with on the order of a
hundred different atom types.
As well as the original implementation, the C22 potential is also widely used in
other molecular mechanics programs. However, many implementations do not match the
genuine one completely, due to differences in parameters or terms missing from the potential
(typically the special 1-4 terms and Urey-Bradley terms). For this reason, validation is neces-
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sary before energies can be compared between ostensibly equivalent programs. The T
implementation of C22 has been carefully validated [184], and was used as the bench-
mark in this thesis.
4.2.4 Coupled-decoupled CBMC
The B CBMC algorithm is incorrect if a pair of atoms defines the central bond in
multiple torsion terms. In this algorithm, all bond angles centred on an atom are determined
simultaneously, by doing a small spherical coordinate Monte Carlo simulation. This results in
angles with the required Boltzmann distribution. After the bond angles have been chosen, the
torsion angle is generated by a rejection scheme. However, if multiple torsions are present,
bond angle bending terms can no longer be selected independently of torsion terms, and
therefore the B algorithm is incorrect [144].
This problem is avoided in the B force field by ensuring that no more than one
torsion term is defined around each pair of bonded atoms, with adjustments to the torsion
and bending parameters of branched molecules to compensate. This approach works with the
united-atom alkane force field and the types of simulations B is designed for, but it is
inappropriate for the accurate implementation of an existing, all atom protein force field. Re-
distributing energy between torsion and bending modes results in discrepancies in conforma-
tional energies, and would be tedious for a force field with many parameters, like C22.
There are various ways to avoid the multiple torsion problem, the most obvious of which
are quite inefficient. For instance, the positions of all atoms bonded to a central pair can be
generated simultaneously using a Boltzmann rejection scheme, or the torsion potential term
can be included in U ext and the number of trial moves increased. A better approach is to
decouple the generation of bond angles, torsion angles, and so on, choosing them by sequen-
tial, biased selections, thus extending the CBMC idea to the internal degrees of freedom.
An additional trick is to couple particular biased selections (for instance, on the torsional and
Lennard-Jones energies), so that each biased selection stage sends multiple possible conforma-
tions to the next selection step.
The algorithm implemented by Martin and Siepmann [144] generates conformations using
coupled torsion and Lennard-Jones selections, while splitting the choice of bond angles into
a series of decoupled selections. Each growth step n proceeds from atom f , with the bonded
atom which is not being regrown designated p (previous). grown is defined as the number of
atoms bonded to f which need to be regrown in step n.
Bond angles are chosen in two stages, a and b. In stage a all angles a − f − p are chosen
independently for a = 1 . . . grown by a selection out of trialsbend trials biased by the bending
potential ubenda . In stage b, the angles b − f − c for b = 2 . . . grown, c = 1 . . . b − 1 are chosen
in grown − 1 biased selections on ubendb . The product of the individual Rosenbluth weights
gives an overall Rosenbluth weight for the bending selections, wBn . Stated formally,
ubenda = ubend(a − f − p)
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ubendb =
b−1∑
c=1
ubend(b − f − c)
wPxn =
trialsbend∑
k=1
exp(−βubendxk )
wBn =
grown∏
a=1
wPan
 ×
grown∏
b=2
wPbn

With all bond bending angles fixed, the torsion angle along f − p is selected based on the
sum of all relevant torsion potential terms. This biased selection is repeated trialsLJ times, and
from these orientations, the coupled selection on the Lennard-Jones potential is determined.
Calculation of the associated Rosenbluth weights is then as follows:
wTi =
trialstors∑
j=1
exp(−βutorsj )
wLn =
trialsLJ∑
i=1
exp(−βuLJi )wTi
The acceptance rule for the new configuration after all growth steps is then simply:
acc(old→ new) = min
[
1,
∏steps
n=1 w
L
n (new)w
B
n (new)∏steps
n=1 w
L
n (old)w
B
n (old)
]
The order in which the atoms are grown must be the same for the old and new con-
figurations. There are also some special cases to be considered for the first two (re)growth
steps.
4.2.5 Implementing CHARMM22 in BIGMAC
The B force field uses a small number of parameters and a handful of atom types. All
internal interactions for a particular molecule must be defined in the associated input file.
Larger molecules with more complex topologies require unwieldy specifications, and when
many parameters are added to the force field, it becomes impractical to prepare input files by
hand. At the same time, writing code to automatically process and assign parameters of a force
field like C22 is error-prone, and entails careful testing and validation.
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Fortunately, the software package T [184] proved to be a suitable source for most
of the routines needed to add the C22 protein force field to B. As the internal
representation of molecules and force fields was quite similar in the two programs, it was
straightforward to adapt T parameter and topology file reading, and parameter assign-
ment code to work with B. At the same time, the B energy evaluation functions
were rewritten to match the C22 functional forms. The resulting program, which al-
lows most of the original B simulation techniques to be used with T-format
topologies and C22-type potentials, was given the name W.
The additional complexity of the force field made changes to the CBMC algorithm ne-
cessary. First, for simplicity, bond lengths are fixed at equilibrium values. This constraint is
used in most protein MD simulations, and appears not to cause any important change in the
behaviour of the system [92]. Second, the improper dihedral, Urey-Bradley, and torsion terms
around a particular atom are in general interdependent. Together with the bond-bending and
non-bonded terms, they were included in a coupled-decoupled CBMC scheme.
The coupled-decoupled algorithm described by Martin and Siepmann [144] works well
when all bond-bending terms centred on an atom are close to orthogonal at their equilibrium
values, but becomes inefficient otherwise (unpublished results). In general purpose force fields
and protein force fields such as C22, the observed equilibrium value for bond angles
deviates significantly from the minimum of the individual bending terms, with the bending
(and potentially other) terms around a central atom counterbalancing each other. Selection
of bond angles in two decoupled stages results in the angles selected in the first stage being
close to their individual minima, but the angles selected in the second stage being far from
equilibrium, giving a low partial Rosenbluth weight. The probability of acceptance becomes
very low, and so overall efficiency suffers.
This problem was solved by using the B approach of a small MC scheme to choose
the bond angles simultaneously (on the basis of the bending, Urey-Bradley, and improper di-
hedral terms) from an equilibrium distribution, in place of sequential biased decoupled selec-
tions. The final scheme is illustrated in Figure 4.3 and is referred to here as MC-CD-CBMC.
As bond lengths and angles may be coupled in C22 via 1-3 Urey-Bradley terms (Fig-
ure 4.4), bond lengths cannot be drawn independently from a Boltzmann distribution as was
done in B. In future, variable bond lengths could be added to the scheme by including
these in the small MC scheme.
B calculates the Coulomb terms of the force field using Ewald summation [72,135,
136]. The energy of a periodic system of point charges is split into two components, a “real-
space” term equal to the Coulombic energy of the point-charges as if screened by Gaussian
potentials, and a “Fourier-space” term or correction, which cancels out the energy due to the
screening potentials, and includes the effects of periodicity. In B, the real-space term is
a pair-wise calculation with a distance cut-off, and is included in the biased selection with the
Lennard-Jones potential. The Fourier-space term is more time-consuming to calculate, so it
is evaluated once per grown molecule as part of the MC acceptance rule, using a parallelised
algorithm.
The total time cost of Ewald summation electrostatic energy evaluation grows as O(n1.5)
(where n is the number of interacting charges in the system), while conventional (non-
periodic) pairwise evaluation with infinite cutoff grows as O(n2 ). However, pairwise eval-
uation is considerably faster for systems with few atoms, so this option was added to the
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Figure 4.4: Interdependence of force field terms
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term structure description C22 types
a. bend
H H
O
TIP3P water HT; OT
b. improper dihedral
C C
H
N
amide
nitrogen
C; NH1; CT1; H
c. Urey-Bradley 1-3
N
C C arginine
Nη1 -Cζ -Nη2
NC; C
d. torsion
C
C
C
C
butane CT3; CT2
Table 4.1: Scheme for validation Monte Carlo simulations of individual bonded force field
terms
W code. As an experiment, an option of using the unscreened Coulomb potential in
the biased selection was also implemented (the difference between screened and unscreened
potentials was added to the Fourier-space energy in the acceptance rule). Inclusion of the
Fourier-space term in the MC acceptance rule results in some reduction in the acceptance ra-
tio, so shifting some of this energy to the biasing potential may in this way improve efficiency.
4.2.6 Validation
Initial testing of W consisted of ad hoc comparisons of conformational energies of a
series of structures, using T (version 3.7, June 1999) as the reference (results not shown).
As a more thorough test of both the force field implementation and the correctness of the
CBMC algorithm, simulated probability distributions for each category of bonded potential
term were then compared with the exact Boltzmann distributions at 300 K. In addition, the
probability distribution of the C1–C2–C3–C4 torsion angle from an (all-atom) simulation of
butane at 1000 K was compared with the distribution from a stochastic dynamics (SD) simu-
lation, in order to check if the Lennard-Jones non-bonded term was correctly implemented,
and as an initial validation of the MC-CD-CBMC algorithm for larger, branched molecules.
A temperature of 1000 K was chosen to improve equilibration in the stochastic dynamics
simulation. The Coulombic non-bonded term was tested in simulations of a united-atom
butane molecule where charges of +0.3 and −0.3 were assigned to C1 and C4 respectively.
The probability distribution of the C1—C4 distance was compared between W and
SD simulations at 1000 K.
The Monte Carlo simulations for the individual force field terms consisted of 320000 MC-
CBMC regrowths, following the scheme in table 4.1. The all-atom butane and Coulomb test
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Figure 4.5: Alanine dipeptide, N-acetylalanine N’-methylamide. Backbone φ and ψ torsion
angles are indicated.
Monte Carlo simulation consisted of 320000 MC-CD-CBMC regrowths. 100 trial positions
were used for the decoupled torsion selections (trialstors = 100), and 8 trial positions for the
decoupled Lennard-Jones selections (trialsLJ = 8). The small MC scheme used 300 MC moves
per placed atom. A cut-off of 9 A˚ was used for Lennard-Jones interactions. No Coulomb term
was used for the all-atom butane simulation; tests of the Coulombic term were done with a
non-periodic pairwise potential and no cutoff.
The stochastic dynamics simulation was performed using the program dynamic from the
T package, modified to use the Allen and Tildesley formulation of the velocity Verlet
stochastic dynamics integrator [9], and to remove velocity scaling and solvent-accessible surface
area calculation code. A friction coefficient (γ ) of 6.5 ps−1 was used, with a step-size of
1 fs, and bond lengths were constrained to their equilibrium value by use of the “Rattle”
algorithm [10]. The SD simulation length was 50 ns and torsion angles were tabulated once
every 1 ps.
Estimates of the probability distributions were obtained from the tabulated data using the
statistics program R [111]. Kernel density estimation [34, 230] was used with a Gaussian ker-
nel, with the smoothing bandwidth chosen using the direct plug-in method [203]. Where
comparisons were made between SD and CBMC results, the larger of the two selected band-
widths was used for both density estimates, to allow a convenient comparison of peak height.
Correlation time estimates for the small MC scheme used to sample bond angles were
calculated for the various trigonal and tetrahedral groups present in the tripeptide Glu-Asp-
Leu. The size of trial moves was chosen to give an acceptance ratio approximately equal to 0.4.
1500 cycles of two (trigonal) or three (tetrahedral) MC moves, equally distributed between
azimuth and elevation moves on a randomly selected atom, were recorded per group, and
correlation times for bending angles, 1-3 distances, and improper dihedrals, were estimated
from block averages.
All simulations were performed under Linux on a 400 MHz Intel Celeron PC with 64 MB
RAM. The g77 F 77 compiler (version “0.5.25 19991030 (prerelease)”) from the
GNU compiler collection was used to compile W and T.
4.2.7 Alanine dipeptide
The blocked alanine molecule, (N-acetylalanine N’-methylamide), commonly known as alan-
ine dipeptide, (see Figure 4.5) is a simple model compound for studying peptide conform-
4.3. Results and discussion 53
ation. The probability distribution of the φ and ψ backbone torsion angles, namely the
Ramachandran plot, describes the most important aspects of the conformational free energy
surface. Details of numerous simulations of alanine dipeptide have been published, making it
a useful benchmark [37, 224]. Gas phase and aqueous solution results using the C22
potential have been obtained from stochastic dynamics simulations [86, 210] and MD with
adaptive umbrella sampling [213], using a variety of solvation models.
A blocked alanine model was constructed using standard C22 atom types, along
with the charges published in [86]. The published SD simulation was performed using the
UHBD program [142], and it is unclear if a full set of C22 potential terms was
used. To ensure consistency of models, an SD simulation using T dynamic was therefore
chosen as the reference for evaluation of W results. Despite the use of bond length
constraints in this simulation, the Ramachandran plot was expected to be qualitatively similar
to those in the literature.
The MC simulation consisted of 700000 MC-CD-CBMC steps at 1000 K, randomly di-
vided with equal probability between full and partial molecule regrowths (where only a subset
of atoms are given a new configuration). Non-periodic pairwise Coulombic interactions were
used, with all other parameters as described for the previous simulations. Alanine dipeptide
has one stereocentre, the Cα atom; the chirality of conformations generated by CBMC was
constrained to be (S)-. Torsion angles were sampled every step. Two shorter simulations of
2000 steps were done to allow the acceptance ratios of the three different Coulomb potential
evaluation schemes to be compared. The SD simulation length was 50 ns and torsion angles
were tabulated once every 100 fs.
Two dimensional kernel density estimation with a bandwidth of 10◦ was used to give
a probability distribution with a degree of smoothing comparable to the histograms in [86].
Convergence of the simulations was followed by plotting the autocorrelation function of the
system potential and the characteristic decay time was estimated from block average plots
[77]. Free energy minima were located on the benchmark Ramachandran plot, and standard
deviations of the probabilities at these minima for both SD and CBMC were calculated by
dividing the simulations into five blocks and making density estimates for each block.
4.3 Results and discussion
The probability distributions derived from CBMC simulations for the individual bonded en-
ergy terms closely match the exact Boltzmann distributions, with the observed minor discrep-
ancies due to the statistical error of the simulations (Figures 4.6 and 4.7). Larger differences
are visible between the MC-CD-CBMC results and SD results for butane (Figure 4.8), but
the SD results have noticeable errors. Despite long simulation at a high temperature, with a
relatively flexible molecule, the correlation time of the stochastic dynamics simulation is still
quite long, and asymmetry in the SD probability distribution is noticeable. The match of
distance probability distributions showing the effect of the Coulomb term is also good (Figure
4.9).
The bond angle MC autocorrelation times found for the various groups in Glu-Asp-Leu
are shown in table 4.2. While the estimates are rough, they indicate that adding 1-3 and
improper terms to the force field only causes a minimal increase in the characteristic decay
time. The 300 cycles per placed atom used to sample the bond angle distribution in the other
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Figure 4.6: Probability distributions for C22 bonded potential terms at 300 K. W-
 observed distribution (solid line) and theoretical Boltzmann distribution (dashed line).
Top: TIP3P water angle bending term (bandwidth 0.35◦). Bottom: amide nitrogen improper
dihedral term (bandwidth 0.58◦).
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Figure 4.7: Probability distributions for C22 bonded potential terms at 300 K. W-
 observed distribution (solid line) and theoretical Boltzmann distribution (dashed line).
Top: arginine Nζ–Cζ–Nζ Urey-Bradley 1-3 term (bandwidth 4.8× 10−3 A˚). Bottom: butane
C1–C2–C3–C4 torsion angle term (bandwidth 2.0
◦).
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Figure 4.8: Probability distribution for C1–C2–C3–C4 torsion angle in all-atom butane model
at 1000 K. W observed distribution (solid line) and distribution from stochastic dy-
namics simulation (dashed line) (bandwidth 2.7◦).
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Figure 4.9: Probability distribution for C1—C4 distance in charged united-atom butane model
at 1000 K. W observed distribution (solid line) and distribution from stochastic dy-
namics simulation (dashed line) (bandwidth 0.018 A˚).
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group τc bend (cycles) τc 1-3 (cycles) τc improper (cycles)
a. NH+3 – 33 14 –
b. –CH– 27 17 –
c. –CH2– 40 20 –
d. CH3– 33 40 –
e. –COO 33 8 5
f. –CO– 27 – 5
g. –NH– 17 – 13
Table 4.2: Bond-angle MC correlation time estimates for groups in Glu-Asp-Leu
simulations should be more than sufficient to ensure that these terms are sampled from an
equilibrium distribution.
The benchmark alanine dipeptide Ramachandran plot from SD simulation (Figure 4.10)
appears very well-converged. The peaks are of similar size, location and shape to the published
results [86], as expected. Once more, convergence is extremely slow, as shown by the presence
of a long “tail” in the autocorrelation plot (Figure 4.13), and a characteristic decay time of 7 ps.
It seems likely that the previously published results from a 2 ns SD simulation are inadequately
converged, despite the length of the simulation, with a similar slow convergence observed in
another SD study of a tripeptide [200]. Due to trapping, this results in a systematic error in
relative peak heights, rather than the more obvious presence of “noise” in the results. The
simulation here required approximately 20 hours of computer time.
The CBMC simulation shows no long tail in its energy autocorrelation function (Figure
4.13), as it is not so liable to trapping in local minima; the characteristic decay time is 45
MC steps. Convergence of the simulation is slowed by a reduced acceptance rate, and this
is reflected in noticeable noisiness in the probability distribution (Figure 4.11), clearly visible
in the difference plot (Figure 4.12). Use of the Coulombic energy term has a marked effect
on the acceptance rate, reducing it from 0.17 to 0.10 (table 4.3) as strong non-bonded in-
teractions either disturb the bond-bending distributions, or have a non-local effect on torsion
distributions via multiple bonds. The CBMC simulation took about six days of calculation
time.
The peaks of the benchmark probability distribution are located close to (−100, 140) and
(70,−85), corresponding to the β and Cax7 conformations in the usual nomenclature. The
probabilities at these peaks are 6.64(±0.21)×10−5 deg−2 (±s.d.) and 1.41(±0.15)×10−5 deg−2,
a free energy difference of 12.9(±0.9) kJ mol−1. The CBMC simulation gives 6.61(±0.55) ×
10−5 deg−2 and 1.12(±0.10)× 10−5 deg−2 at the same coordinates. These results confirm that
the CBMC results agree with the benchmark to within the bounds of statistical error.
The CBMC simulation does not equal the precision or efficiency of the SD benchmark
simulation. Assuming the statistical errors are proportional to 1/
√
n, where n is the number
of MC moves, a CBMC simulation roughly seven times longer would be required to equal
the precision of the benchmark. Taking into account the number of non-bonded trial moves
(nchlj), this would mean that the CBMC simulation required as many non-bonded energy
evaluations as SD. The number of bonded energy calculations would be on the order of a
hundred times higher, as reflected in the relative execution times of the simulations reported
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Figure 4.10: Ramachandran plot of alanine dipeptide backbone φ, ψ torsion angle probability
distribution. 50 ns Stochastic dynamics simulation (benchmark).
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Figure 4.11: Ramachandran plot of alanine dipeptide backbone φ, ψ torsion angle probability
distribution. W MC-CD-CBMC simulation.
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scheme acceptance ratio CPU time (seconds)
no electrostatics 0.17 9210
Ewald 0.10 10200
Coulomb 0.06 9450
Ewald (selection on unshielded potential) 0.06 10060
Table 4.3: Efficiency of Coulomb evaluation schemes for alanine dipeptide
here. However, the cost of bonded energy evaluations will be relatively small with larger
systems, making this less of a concern in practice.
At lower temperatures (e.g. 300 K) SD exhibits extremely slow convergence [90, 200], so
a comparison of CBMC with other techniques, such as adaptive umbrella sampling, is more
appropriate. High energy regions of the free energy surface are poorly sampled by CBMC,
but for high Boltzmann weight conformations, CBMC appears to have comparable efficiency
to umbrella sampling. For instance, for the calculation of the free energy difference between
the two lowest minima on the Ramachandran plot of alanine dipeptide [213], CBMC re-
quires approximately the same number of non-bonded energy evaluations to achieve a result
of the same precision. Simultaneous umbrella sampling of numerous internal degrees of free-
dom is impractical, so for conformational analysis of larger peptides, CBMC should have the
same attractive features as parallel tempering, entropy sampling and other generalised ensemble
techniques.
Comparison of the different Coulomb evaluation schemes in table 4.3 indicates that the
original Ewald implementation in B is the most efficient for this system. The additional
Fourier-space sum does not seem to use a large amount of extra CPU time compared to the
non-periodic pairwise Coulomb evaluation, even for a system of this modest size. This result
may not be generally applicable, though strong fluctuations in the Coulomb energy have been
noted as a possible source of problems in another biased MC study of peptides [20].
4.4 Conclusions
CBMC algorithms have previously been applied to simple force fields appropriate for highly
flexible molecules such as alkanes. Implementation of a standard protein force field demon-
strates that in principle CBMC is more widely applicable, though a more involved algorithm
is required when there are numerous interdependent terms in the bonded potential. The
additional energy evaluations necessary for a coupled-decoupled scheme, and for a small MC
scheme, reduce the speed-up obtained to some extent, but the goal of performing fewer ex-
pensive (non-bonded) energy evaluations at the cost of more inexpensive (bonded) evaluations
remains intact. The efficiency is comparable with umbrella sampling for the evaluation of po-
tentials of mean force, making it interesting for applications in conformational analysis. The
speed-ups possible from parallelisation and dual-cutoff optimisation remain attractive.
The CBMC algorithm used in W is also suitable for other protein force fields (e.g.
A 94 [50]) and even general-purpose force fields with cross-terms, such as MMFF94
[93]. However, the decoupling of torsion angle selection from the other bonded terms will
result in inefficiency (namely, low acceptance ratios), if these are appreciably non-orthogonal.
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There may also be better formulations of the small MC scheme possible, particularly for non-
tetrahedrally-hybridized atoms, or where a combination of stiff and flexible modes are present.
4.4.1 Limitations
The major deficiency of W (which is characteristic of many CBMC algorithms) is an
inability to perform simulations of cyclic molecules, from simple benzene rings to cyclic poly-
peptide chains, as the stepwise growth algorithm has no provision to close rings. Concerted
rotation schemes for cyclic peptide chains have been described and implemented [54,199,253],
and more recently an algorithm which can be applied to arbitrarily large cycles [228], but these
involve an expensive polynomial root-finding operation. For small, relatively stiff rings with
a few low energy conformations, a simpler approach should be possible. Introduction of aro-
matic rings into the simulation scheme as rigid subunits seems a reasonable approximation,
which would allow simulation of a much broader range of peptides without radical changes
to the CBMC algorithm. Other possibilities would be the use of another small MC scheme,
or a library of precalculated conformers.
Most Monte Carlo algorithms become inefficient when dealing with systems at high dens-
ity, such as liquid water at 300 K. Equilibration becomes very slow, and the acceptance ratio
of trial moves may become impractically low. Insertion of a molecule into the system (e.g.
in a grand canonical simulation) depends upon the presence of a suitably-sized cavity, which
for larger molecules and higher densities is very unlikely. A CBMC move under the same
circumstances will almost always result in the regrowth of a conformation (nearly) identical to
the old one. Explicit simulation of the solvent for a system like a peptide in water is therefore
impractical.
A related problem is that the selection of atom positions in a growth step can affect the
choices available in all subsequent growth steps, forcing them into energetically unfavourable
regions (a similar effect is seen in Metropolis MC when it is performed in torsion space). If
partial regrowth moves are possible, the result will be that chain ends will equilibrate more
quickly than middle segments. Adding “look ahead” to the CBMC algorithm (along the lines
of Meirovitch’s scanning method [148,149]) is one way to deal with this problem (see further
the discussion in the following chapter), but the use of hybrid MC moves [67], or concerted
rotations [63] also helps.
Despite the ability of CBMC to avoid trapping in certain types of local minimum, the
presence of numerous non-bonded interactions like hydrogen bonds can stabilise the system
to such an extent that correlation times become very long. The methods to increase barrier-
crossing mentioned in the introduction, for instance parallel tempering, can also be used with
CBMC when this becomes a problem.
Chapter 5
CBMC: applications
5.1 Introduction
The flexibility of polypeptide chains means that thorough conformational analysis is a necessary
ingredient of any study at the molecular level. The development of peptide or peptidomi-
metic ligands by structure-based methods requires insight into ‘the bioactive conformation’,
while predictive simulations require adequate sampling of the relevant conformations. Con-
formational analysis by unconstrained search is futile, as the numerous internal degrees of
freedom combine to give astronomically large numbers of possibilities. Monte Carlo (MC)
and molecular dynamics (MD) simulations are more workable methods, but nonetheless, slow
equilibration is the rule; a particular problem are the potential energy barriers impeding the
inter-conversion of various low energy conformations.
As described in the previous chapter, configurational bias Monte Carlo (CBMC) sampling
is an efficient simulation method, which may have advantages for the conformational analysis
of peptides. One particular application is docking [126], a simplified form of free energy
simulation. In this chapter, the binding of a tripeptide to a rigid protein receptor was used
as a test case for CBMC. The performance of the CBMC simulation was compared to an
established docking program, AD, in reproducing the complex known from an X-
ray crystallography experiment. A particular focus was the efficiency of the two methods.
5.1.1 Free energy simulations
The essential aspects of biomolecular recognition are generally amenable to a thermodynamic
description in which the equilibrium constant (or equivalently, the free energy difference
between the bound and free states) is central. Molecular simulations are no different from
physical systems, in that absolute free energies cannot be observed directly. This means that
free energy differences can only be derived from (often multiple) simulations which encompass
a process that transforms the system between the two end-states (for instance, thermodynamic
integration). Phase equilibria have been studied extensively by simulation, and a variety of
techniques have been developed to determine free energy differences accurately. Equilibria
involving multiple species are more complex, and barriers along the reaction pathway (such as
diffusion barriers, or the formation of a transition state) make adequate sampling a problem.
Fortunately, simulations are not restricted to physically meaningful reaction pathways, so many
of these barriers may be bypassed with specially constructed simulation schemes.
The most successful type of simulations of receptor–ligand (or equivalently, host–guest)
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binding equilibria have been predictions of the difference in free energy of binding between
two similar ligands for a particular receptor. Simulating the free energy change for the trans-
formation from one ligand to the other, in free and bound states, gives the desired quantity
according to a simple free energy cycle [38]. This technique requires a tightly-bound com-
plex which exhibits no dissociation on the simulation time-scale, and the absence of major
differences in conformation between the two ligands. The modest difference between the
two systems reduces the amount of sampling necessary to follow the transformation process
to convergence, and reduces the need for lengthy equilibration to allow the solvent to relax.
The effect of inadequacies in the potential (particularly with respect to accurate free energies
of solvation) is also minimised.
Adsorption isotherms of linear and branched alkanes in zeolites can be simulated with
excellent accuracy using grand canonical ensemble simulations [211]. Direct application of
the same methods to the binding of peptide to protein is hampered by a number of factors.
Both systems are characterised by slow equilibration, but for zeolite adsorption this is caused
primarily by a diffusion barrier, easily overcome by the particle insertion method of the grand
canonical simulation scheme. More significant impediments to equilibration in the case of
biomolecular binding are the large phase space accessible to both ligand and receptor, which
is only slowly explored, and the presence of a relatively high-density solvent, which relaxes
slowly. A dense solvent also greatly decreases the efficiency with which particles can be added
to the system (particle insertion moves). A general solution to this problem may be found in
the use of continuum solvent representations, or new types of Monte Carlo moves, while the
problem of flexibility of ligand and receptor can be addressed with CBMC techniques.
CBMC greatly increases the efficiency of simulations of the zeolite adsorption of long
alkane chains, by allowing inserted chains to conform to the zeolite matrix, giving net low
interaction energy and an increased acceptance ratio. The Henry coefficient, directly related
to the excess chemical potential of the inserted species, can be determined at the time of
insertion with little additional calculation. Application of CBMC to ligand–receptor binding
should similarly lead efficiently to low energy bound complexes. A crude, but nonetheless
useful approximation would be to treat the receptor as a rigid species, and perform simulations
in vacuum, thereby achieving much faster equilibration. This application of CBMC resembles
the well-established idea of docking.
5.1.2 Docking and scoring
An inability to perform realistic simulations to determine the free energy of binding from first
principles has led to the development of numerous other computational approaches which
qualitatively or semi-quantitatively characterise the binding process. As knowledge of the
structure of the bound complex is pivotal for further experimentation, the goal of many
specialised computational techniques is to predict it when experimental details (e.g. from
NMR or X-ray crystallography) are unavailable. Docking is equivalent to finding the most
densely populated state (or family of states) in the ensemble, assuming equilibrium conditions
which strongly favour binding. Docking procedures are generally carried out when ligand and
receptor are known to bind with high affinity, with a known receptor structure, and sometimes
a predetermined ligand conformation. Under these restrictions, a number of docking programs
have been developed which can predict the bound complex successfully. A related problem is
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the analysis of a bound complex to give a ‘score’, a rough approximation to the free energy
of binding. The approximate nature of scoring limits it to the qualitative comparison of
hypothetical ligand–receptor complexes from docking studies or de novo ligand design. The
shortcomings of empirical approaches to molecular recognition noted in the introduction are
evident in most scoring procedures, however there are rarely any better alternatives.
Current docking and scoring approaches have serious limitations when applied to flex-
ible polypeptide ligands. For docking this is a simple consequence of inefficient sampling of
peptide conformation. Scoring programs perform badly for all the reasons already mentioned,
but are further impeded by formulations and parameterisations appropriate for smaller, much
less flexible ligands. As computational studies of peptide ligands are poorly served by these
methods, it would be interesting to see if docking methods based on the improved sampling
efficiency of CBMC can perform any better.
5.1.3 AUTODOCK
AD [88] searches for low energy ligand–receptor complexes using a Metropolis MC
algorithm together with a simulated annealing procedure. A variant of the A united-
atom protein potential is used, with efficient grid-interpolation energy evaluation possible due
to the assumption of a rigid receptor. Docking is performed without explicit solvent, with
an approximate implicit treatment of solvation using a distance-dependent dielectric constant.
MC moves consist of rigid body displacements and rotations of the ligand, and changes to
designated ligand internal torsions. Version 3.0 of the AD software [163] implements
a number of more elaborate features. In addition to Metropolis MC, a genetic algorithm
search strategy with a local search optimisation step is available. There is an improved implicit
solvation model, using atomic solvation parameters, and energy evaluations use an empirical
free energy function, rather than the simplified A potential.
A gave a reasonable result for the docking of a relatively flexible, hydro-
phobic HIV-1 protease inhibitor, XK263, with the lowest energy docked conformation
having an RMSD of 0.86 A˚ from the crystal conformation [164], and also did well with
other more straightforward systems, including benzamidine/β-trypsin and streptavidin/biotin
[88,163,164]. Docking of highly flexible ligands (those with more than eight rotatable bonds,
as a rule of thumb) is not possible within a reasonable length of time using the simulated an-
nealing protocol [163], and while the genetic algorithm has been shown to cope better with
flexibility in a number of cases, the most flexible ligand successfully docked had eleven rotat-
able bonds. To work around this limitation, strategies for the docking of peptides have been
proposed that use additional assumptions about the nature of binding, for instance by serial
docking of fragment sequences [78].
5.1.4 Parallel tempering
Dynamic simulation schemes which sample a canonical ensemble suffer from poor sampling
when barriers are present on the potential energy surface. Various non-Boltzmann sampling
techniques (generalised ensemble or entropy sampling for instance) simulate a non-physical
ensemble with an increased population of higher energy states. The generalised ensemble is
constructed to allow the reweighting of simulation results to recover a canonical ensemble.
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Figure 5.1: Parallel tempering histograms of energies for parallel systems. Regions of overlap
indicate the probability of swaps between adjacent systems. Energies taken from conforma-
tional analysis of alanine dipeptide.
Related ad hoc approaches based on high-temperature equilibration, most notably simulated
annealing, also achieve improved barrier crossing behaviour, though the usual implementations
do not give a route to a conventional ensemble average. Parallel tempering [82, 95] (also
known as the multiple Markov chain or replica-exchange method), is an elegant alternative to
generalised ensemble techniques, with much of the simplicity of simulated annealing, as well
as the virtues that it is easy to parallelise and uses few adjustable parameters.
Parallel tempering requires multiple independent copies of the simulation run in paral-
lel, each at a different temperature. One simulation runs at the desired temperature, and
the remaining systems in a “ladder” of increasing temperatures. At regular intervals dur-
ing the simulation a pair of systems adjacent on this ladder is chosen at random. A swap
of configurations between the two systems is attempted, with an MC acceptance rule using
the instantaneous energies of the two systems, along with their difference in temperature,
acc[(i, j) → ( j, i)] = min[1, exp(−1Ui j/kB1Ti j )] (Figure 5.1). If the temperatures are chosen
to give a reasonable acceptance rate (e.g. greater than 10%), each system continues to sample
a canonical ensemble at the given temperature, but mixing between the systems produces an
enhanced probability of overcoming any free energy barriers.
Verkhivker et al. have applied parallel tempering to the ligand–protein docking prob-
lem [232]. Parallel tempering MC was used as a follow-up to docking using the method of
evolutionary programming. Either the A force field with an additional implicit solvation
term, or a simplified knowledge-based potential function was used. The parallel tempering
simulations gave a detailed picture of the free energy landscape near the docked conforma-
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Figure 5.2: The tripeptide HIV-1 protease inhibitor, Glu-Asp-Leu (EDL).
tions, and in some cases were able to correct misdockings which were the result of inadequate
sampling in the evolutionary programming docking step.
5.2 Methods
5.2.1 Models
The chosen receptor was the HIV-1 protease dimer, and the tripeptide competitive inhibitor
Glu-Asp-Leu (EDL) (which binds with a Ki of approximately 50 µM at pH 4.25 [139]) was
the mobile species (Figure 5.2). Global features of the HIV-1 protease dimer and the position
of the binding site can be seen in Figures 5.3 and 5.4. The two loops centred around Ile50 are
known as the ‘flaps’, and an ‘opening’ movement of these resulting in an increased exposure
of the active site to solvent has been observed in the apoenzyme. The closed state, which
is observed in crystal structures, offers very limited access to the active site, a challenge to
docking studies.
Microcalorimetric measurements have indicated that the binding of EDL to HIV-1 pro-
tease is exothermic, with a 1H of −15.1 kJ mol−1 [229]. Combined with an examination of
the crystal structure, this suggests specific polar interactions are essential for binding. This is
in contrast to other protease inhibitors that are thought to bind primarily because of their hy-
drophobicity, consistent with the observed positive entropy change on binding. Furthermore,
binding of the inhibitors acetyl-pepstatin, indinavir, saquinavir and nelfinavir is enthalpically
unfavourable [229]. In the absence of solvent, hydrophobically-driven binding is impossible,
making an exothermic binding process more or less a prerequisite for simulation in vacuum.
A model of the protease was built starting from the X-ray crystal structure 1a30 [139]
(resolution 2.0 A˚, R factor 0.189) from the Protein Data Bank [25,26]. Hydrogen atoms were
added and their coordinates minimised using the CFF91 force field [62, 143] in MSI Insight
2000 [160], with the protonation state of ionisable residues as tabulated by Insight for pH 4.3
(exceptions noted below). For the simulations with W, the side chains of the exterior,
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Figure 5.3: Ribbon diagram of HIV-1 protease dimer crystal structure, with bound inhibitor
EDL. Coordinates taken from PDB 1a30.
Figure 5.4: Ribbon diagram of HIV-1 protease active site, with bound inhibitor EDL. Co-
ordinates taken from PDB 1a30.
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Figure 5.5: Schematic L representation of the HIV-1 protease EDL binding site, as
derived from the Protein Databank X-ray crystal structure 1a30. Hydrogen bonds where Asp
Oδ2 is a donor have been added by hand.
72 CBMC: applications
solvent-exposed residues Lys7, Lys14, Arg41, and Lys41 were removed from both monomers
to restore electrostatic neutrality (this was a requirement to ensure the accuracy of the Ewald
sum). Binding of the ligand is pH-dependent [139] indicating pKa shifts in ligand and/or
receptor in the bound form. The results from Chapter 2 indicate that at pH 4.3, the N-
terminus, C-terminus, and aspartic acid side chain of the tripeptide will be fully protonated,
while the glutamic acid side chain will be on average approximately 50% protonated. The
catalytic aspartate dyad of the enzyme will be 70% monoprotonated and 30% diprotonated.
However, the modelled ionisation state was selected in ignorance of these results, based on
hydrogen-bonding analysis published by the crystallographers [139], and the requirement that
the ligand be electrostatically neutral. Both Asp25 residues were modelled as protonated and
the ionisation state of the tripeptide was modelled as +HGlu-Asp-Leu-O− (i.e. the Glu and
Asp sidechains are protonated). A L [241] representation of the tripeptide binding site
is reproduced in Figure 5.5. The protease coordinates remained fixed in all simulations. All
crystallographic water molecules, except the well-known flap water (number 1097 in 1a30)
and three other water molecules present in the interface (1075, 1076, 1092) according to
L analysis, were removed.
5.2.2 AUTODOCK
Both AD versions 2.4 and 3.0 were used, to allow comparison with two different
docking protocols. The simulated annealing docking algorithm of AD 2.4 is based
on a straightforward Metropolis MC scheme, making a comparison with W easier.
On the other hand, the more elaborate approach embodied in AD 3.0 is probably
needed for successful docking with a highly flexible ligand, and gives a better impression of
the current state of the art.
The Insight models of protein and peptide, with CFF91 charges, were saved in MOL2
format, and standard AD scripts and protocols were used to generate the required
input files, with the ligand model automatically converted to an essential-hydrogens rep-
resentation. Grids for potential evaluation had a resolution of 0.375 A˚ and dimensions of
45 A˚ × 45 A˚ × 45 A˚. Each docking was repeated 100 times with different random seeds, after
which results were clustered and ranked by energy. The simulated annealing protocol con-
sisted of cycles which continued until either 25000 steps were accepted or 75000 rejected.
Each cycle was started with the current minimum energy configuration. In a previous study
with AD, a high starting temperature was needed to give the HIV-1 protease inhib-
itor XK-263 enough energy to enter the active site [164], so a similar protocol was followed
here. The initial cycle of each run was at a temperature of 31000 K, which was multiplied by a
factor of 0.955 before each subsequent cycle.The initial maximum displacement of translation
steps was 20 A˚, and of quaternion rotations 180◦; both were multiplied by a factor of 0.985
per cycle. No initial energy limit was specified. The run was stopped after 150 cycles.
The Lamarckian genetic algorithm parameters were left at the AD 3.0 default
values. These were a population size of 50, a maximum of 1 500 000 energy evaluations,
a maximum of 27 000 generations, a survival rate of one elite individual per generation, a
mutation rate of 0.02, a crossover rate of 0.8, a window size of 10 generations for picking
the worst individual, and α and β values for the mutation Cauchy distribution of 0 and 1.
Step sizes were 0.2 A˚ for translations, 5.0◦ for quaternions and 5.0◦ for torsions. Pseudo-
5.2. Methods 73
Solis and Wets local search was performed for 300 iterations, with a probability of selecting
an individual for search 0.06. The initial value of ρ was 1.0, with the value updated after 4
consecutive successes or failures, and a lower bound of 0.01. A maximum initial energy of 0
was specified, with a a maximum of 10 000 retries. 100 runs were performed.
The dockings were first done with the peptide constrained to the conformation seen in
the crystal structure of the complex. This was to ensure that the experimental complex was
an energy minimum in the AD model, and that the binding site was sufficiently
accessible. In the second round of dockings all σ-bond torsion angles (namely, all backbone φ
and ψ angles, and all sidechain χ angles) were free to rotate, for a total of 15 rotatable bonds.
AD was run under Irix 6.5.5 on an SGI Origin 200 R10000 180 MHz, and was
compiled using the SGI MIPSPro C compiler version 7.30.
5.2.3 WHOPPER
A parallel tempering scheme was added to W, using the Message-Passing Interface
(MPI) [151] to achieve parallel execution of the multiple systems. For the types of simulation
described here, the communication overhead required for parallel tempering is low, so n
processors for n parallel systems should represent a close to factor n linear speed-up relative to
the single processor case. The parallelisation was orthogonal to the parallel algorithms already
implemented in W, so existing speed gains can still be achieved in combination with
parallel tempering.
The B CBMC simulation scheme for alkane adsorption in a zeolite matrix was
the basis for docking simulations in W. The protein receptor was treated as a fixed
collection of atoms, interacting with the mobile, peptide species using C22 Lennard-
Jones parameters and charges. All intra-molecular bonded and non-bonded interactions of the
protein were ignored. In order to achieve workable execution times, the mobile species was
simulated using C19 essential hydrogens bonded and non-bonded parameters, rather
than the all-atom potential. Electrostatic interactions appeared to have a serious negative effect
on the efficiency of the simulation, so in addition to simulation with the standard parameters,
the simulation was also performed with ligand charges scaled by 0.1. Simulations were carried
out in the canonical ensemble (constant-NVT) with periodic boundary conditions. Dimen-
sions of the simulation box were chosen large enough (60 A˚ × 70 A˚ × 70 A˚) to prevent large
artefacts from the Ewald sum evaluation of long-range Coulombic interactions [108].
Parameters of the CBMC simulations were as described in the previous chapter. As only
one mobile particle was present in the system, no tail correction was applied to the Lennard-
Jones interactions. Ewald summation was performed with α = 0.35 and 21× 24× 24 vectors.
Chirality of the Cα atoms of the tripeptide were constrained to be (S). The system energy and
coordinates were sampled every cycle of 10 CBMC moves. A series of 64 parallel tempering
moves were attempted at the end of each MC cycle. The docking simulation consisted of
500 cycles of 10 steps, with 50% complete regrowth and 50% partial regrowth. No additional
initialisation/equilibration cycles were used. System temperatures for parallel tempering were
300 K, 350 K, 400 K, 450 K, 500 K, 600 K, 700 K, and 800 K.
Each system was initialized with the ligand displaced 20 A˚ from its bound position. Com-
plete chain regrowths were performed starting from Cγ of the aspartic acid residue and to
speed up the simulation, this start atom was always placed at the coordinates of the corres-
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program lowest energy RMSD
kJ mol−1 A˚
AD 2.4 (rigid) −362 0.5
AD 2.4 (flexible) −129 17.6
AD 3.0 (rigid) −3 0.2
AD 3.0 (flexible) +10 8.5
W +352 47.4
W (scaled q) −56 1.9
Table 5.1: Summary of docking results. The energy and RMSD (over all ligand atoms) of the
lowest energy conformation found, relative to the crystal structure conformation, are listed.
ponding ligand atom from the complex, rather than at random. As the binding site is relatively
inaccessible and quite constrained, it is possible to make a reasonable estimate of the degree
to which this accelerates the docking. Partial chain regrowths were initiated from a randomly
chosen atom, as in the previous chapter, and all atoms, including the Asp Cγ , were free to be
regrown in a new position.
An additional series of simulations to measure efficiency in relation to system size were
done using all-atom n-alkane models varying in size from CH4 to C19H40. C22
aliphatic carbon parameters were used, with Coulombic interactions neglected. Simulations
were of single, isolated chains, at 300 K, with CBMC regrowth moves only. Each simulation
consisted of 3000 steps, during which the acceptance ratio was recorded. Other parameters
were identical to the previously described CBMC simulations.
Simulations were performed on a cluster of dual-processor 500 MHz Intel Pentium III
machines, running under Linux 2.2.14. The LAM 6.3.1 [130] implementation of MPI was
used, and programs were compiled using the Portland Group Fortran 77 compiler, version 3.0-
4. Inter-node communication for parallel simulation was over switched, full-duplex 100 Mbps
Fast Ethernet. Parallel tempering simulations used one processor per temperature.
5.3 Results
5.3.1 Docking
A summary of the results of the dockings is given in Table 5.1. Rigid dockings with both
versions of AD successfully found a docked ligand conformation with an RMSD of
less than 0.5 A˚ from the crystal structure as the minimum energy of the simulation. The rigid
docking with AD 2.4 found a conformation with an energy 362 kJ mol−1 lower in
energy than the conformation from the crystal structure, as the latter had a slight steric over-
lap at the N- and C-termini according to the AD 2.4 potential function. Docked
and crystal conformations were much closer in energy as calculated with the AD 3.0
potential function, which has scaled-down Lennard-Jones parameters and applies a smoothing
factor to repulsive terms. The docking with version 2.4 was not reliable, as the native struc-
ture was only found in one of a hundred runs, and no near-native structures were found. This
was despite the use of an elevated starting temperature and an extended cooling programme.
AD 3.0 found eight structures in the cluster with the lowest docked energy, indic-
5.3. Results 75
Figure 5.6: W lowest energy docked conformation overlaid with crystal structure
conformation. The docked structure is drawn in a darker shade.
ating that conformational sampling was good. In addition, the two next most highly ranked
clusters, with a total of 12 members, were on average 14 kJ mol−1 higher in energy than the
minimum, as compared to a jump of 227 kJ mol−1 between the highest and second-highest
ranking structures for AD 2.4.
Dockings in which the ligand torsions were free to move were unsuccessful in finding the
native conformation for both AD versions. In both cases, there was a complete lack
of clustering in the docked structures, with an essentially flat distribution of energies. This
suggests that the sampling was far from converged in both cases, even though on the order of
109 conformations were evaluated, for a total of 42 hours run time, in the AD 2.4
computation.
The scaled-charge W simulation converged to a lowest energy docked conform-
ation with an energy ∼ 50 kJ mol−1 lower than the native conformation. This conformation
had an all-atom RMSD of 1.9 A˚ from the native coordinates, and is shown overlaid with the
crystal structure in Figure 5.6. The structure with the lowest RMSD from the native coordin-
ates, 1.2 A˚, (considering only the ensemble at 300 K) had an energy 27 kJ mol−1 lower than
the native conformation. Unsurprisingly, the strong scaling-down of the electrostatic energies
changes the shape of the potential energy surface and the location of minima significantly.
Nevertheless, the docked structure preserves essentially all the hydrogen bonds seen in the
crystal structure, with the only significant deviation in coordinates in the glutamic acid side
chain. This side chain is partially solvent exposed in the crystal structure, and is noted by the
crystallographers to be disordered [139]. The W simulation using standard parameters
failed to find any docked conformations.
Despite the low efficiency of the CBMC moves (see below), the docking appears to
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Figure 5.7: Histogram of energies of the 162 unique conformations sampled in the W
docking simulation at 300 K.
System temperature (K)
300 – 350 – 400 – 450 – 500 – 600 – 700 – 800
Swap % 26 16 29 55 32 54 59
Table 5.2: Proportion of successful parallel tempering swap moves between the systems.
be well converged. Of the 162 unique conformations sampled at 300 K, 11 cluster within
0.5 A˚ RMSD from the minimum. The histogram in Figure 5.7 shows a concentration of
conformations in the lower energy range.
5.3.2 Parallel tempering
Time series of the four lowest temperature systems are show in Figure 5.8. Exchanges of
conformation between systems as a results of parallel tempering moves can be seen as the
points where the energy traces touch. The highest temperature trace fluctuates in energy
much more strongly than the lower temperature traces, and the parallel tempering scheme
makes use of these fluctuations to enhance the sampling of the lower temperature systems,
resulting in a rapid decrease in energy at the lowest temperature. The percentages of successful
parallel tempering moves are given in Table 5.2. The values are in the range 15% to 60%,
showing substantial mixing between the systems. However, longer equilibration would be
needed to reliably characterize the swap rate. The docking simulation is too short to allow
accurate analysis of the convergence behaviour, but the effect can be seen clearly in the energy
autocorrelation of a longer CBMC simulation of alanine dipeptide with and without parallel
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Figure 5.8: Energy time series for the four lowest temperature systems. Energies are relative
to the lowest energy found in the simulation. Samples were taken once per cycle of 10 MC
steps.
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Figure 5.9: Autocorrelation of system energy at 300 K, single system versus parallel tempering.
Results taken from CBMC simulation of alanine dipeptide (not shown).
tempering in Figure 5.9 (results obtained using the alanine dipeptide model from Chapter 4).
Without parallel tempering, the autocorrelation function decreases rapidly and then flattens
out, suggesting that there is a bottleneck slowing the progression between the various low
energy states. The parallel tempering autocorrelation function decreases more rapidly for
times of approximately 8 cycles or more, with the mixing between high and low temperature
systems allowing potential energy barriers to be more quickly overcome.
5.3.3 Efficiency
Docking
The acceptance ratios for the docking simulation with scaled charges are given in Table 5.3.
Both the proportion of chain growth completed without overlaps, and the proportion of
moves accepted, increases with temperature, as expected. When unscaled charges were used,
there were no successful whole chain regrowth moves for the length of the simulation. The
acceptance ratio for these moves was so low that there were no successful moves even in a
longer simulation (∼ 15000 steps; results not shown).
The computational requirements of the different simulations are summarized in Table 5.4.
The number of bonded and non-bonded energy evaluations carried out by W are
estimates based on the number of trial moves used for the various internal degrees of freedom,
and will vary slightly according to the molecular topology. AD uses a simplified
potential function and the grid-based interpolation method allows non-bonded energies to
be evaluated quickly. The CPU time per step is therefore much smaller than for W,
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system temperature (K)
300 350 400 450 500 600 700 800
whole % 10 12 13 15 16 17 19 19
whole accept 0 0 0 2 0 2 0 2
partial % 50 56 64 75 82 99 100 100
partial accept % 5 6 8 13 16 23 21 22
Table 5.3: CBMC acceptance ratios for the parallel systems, scaled charge results. The first two
rows of results show the percentage of whole chain regrowth moves completed successfully
(i.e. not rejected due to steric overlap), and the number of moves accepted (of 1481 attempts).
The next two rows give the same figures for partial chain regrowths, with the acceptance ratio
given as a percentage in this case.
program total steps bonded non-bonded CPU time
energy evals energy evals seconds
AD 2.4 (rigid) 8.9 × 108 – 8.9 × 108 5.2 × 104
AD 2.4 (flexible) 9.3 × 108 9.3 × 108 9.3 × 108 1.5 × 105
AD 3.0 (rigid) 1.5 × 108 – 1.5 × 108 2.1 × 104
AD 3.0 (flexible) 1.5 × 108 1.5 × 108 1.5 × 108 4.9 × 104
W 5.0 × 103 ∼ 5.0 × 106 ∼ 4.0 × 104 2.8 × 103
Table 5.4: Energy evaluation statistics and CPU use for AD and W. W-
 figures apply to a single system in the parallel tempering simulation. Note that A-
D and W CPU times were obtained on different computers.
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Figure 5.10: Log-linear plot of CBMC simulation acceptance ratio versus alkane chain length.
An all-atom model with C22 parameters was used. The regression line indicates an
exponential decrease in acceptance ratio with increasing system size, r = 1.087e−0.137n
where no such optimizations have been used. The total number of steps, and the number
of energy evaluations performed allow the various algorithms to be compared independently
of the performance of a particular computer system or the degree to which the implementa-
tions have been optimized. However, as the CBMC algorithm uses relatively more bonded
energy evaluations than non-bonded, with the expectation that the former will be less com-
putationally expensive, the net difference in performance from MC will depend strongly on
the implementation.
Alkanes
Simulations with a series of all-atom alkane models showed that efficiency, as measured by the
acceptance ratio of CBMC whole chain regrowth moves, decreases exponentially with chain
length. A log-linear plot of acceptance ratio in relation to chain length (Figure 5.10) indicates
that efficiency is poor for C20H42 and longer.
5.4 Discussion and conclusions
5.4.1 Docking
The system of HIV-1 protease and inhibitor simulated in this chapter is a particularly challen-
ging one. The problem of ligand flexibility is most important, but the inaccessibility of the
binding site, the relatively poor affinity of ligand for receptor, and the unusual protonation
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state of the ligand and receptor all contribute. By exploiting a priori knowledge concerning
the location of the binding site and its protonation state, the CBMC docking simulation using
W successfully found a low energy docked conformation with the same binding mode
as observed in the crystal structure of the complex. Similar conformations were obtained from
rigid docking simulations using AD, with substantially more reliable results using the
genetic algorithm search procedure in AD 3.0. The failure of flexible docking us-
ing both AD versions demonstrates that the conformational freedom of the tripeptide
ligand causes a substantial increase in the size of the problem space which needs to be explored.
The size of the problem space was artificially restricted for the CBMC docking by con-
straining whole chain regrowth to start with the initial atom correctly placed; no additional
constraints were placed on the conformation of the ligand. A reasonable estimate of the effect
of this constraint on the speed of convergence can be made by considering the total number of
possible starting positions in the vicinity of the protein. Assuming that placement of the atom
within a volume of 1 A˚3 surrounding the position in the native structure will be sufficient (a
requirement which will probably be less stringent in practice, as partial chain regrowths may
be able to optimize the atom position subsequently), and given a box volume of 100 000 A˚3,
minus a protein-occluded volume of 26 000 A˚3 (calculated with G), then on the order of
a factor 80 000 speed up was achieved. Combining this information with the data from Table
5.4 gives an estimate of a simulation length for an unconstrained docking of 4.0 × 108 steps,
requiring 4 × 1011 non-bond energy evaluations and 3.2 × 109 bonded-energy evaluations, a
workload in the range of about 3–500 times greater than that presented by the AD
2.4 simulations. In practice the binding site may be known or easily predicted, so these figures
represent a worst case. Use of parallel CBMC within each system will allow further speed-ups;
this analysis assumes that the computational costs of the parallel systems are not summed.
As no indication of the speed of convergence of the flexible AD simulations is
available, no meaningful comparison with the performance of CBMC is possible. However,
the CBMC docking algorithm in its present form does not meet its potential, as convergence
is still much too slow to allow equilibrium simulations and the calculation of free energies
and bulk properties. Pure docking applications may be more practical, but would require
extensive optimizations along the lines of AD. This would entail the use of a simpler
potential function with fewer degrees of freedom in the ligand, making substantial increases in
efficiency possible at some cost to the elegance and generality of the approach.
5.4.2 Efficiency
The efficiency of CBMC for all-atom polypeptide simulations was disappointing. Un-
doubtedly, many parameters require tuning, namely the number of trial moves for the dif-
ferent biased selections, and the second cut-off distance for the dual-cutoff scheme, but such
improvements will not radically improve the acceptance ratio. As illustrated by the series of
alkane simulations (Figure 5.10), the acceptance ratio decreases exponentially with system size.
It is a characteristic of Rosenbluth sampling that the distribution of chain conformations di-
verges from Boltzmann statistics exponentially as the chain length increases [22]. For simple,
linear systems this divergence does not affect the acceptance ratio appreciably except when
the chains are extremely long. The failure of CBMC in this case appears to be a general
problem for highly branched systems of moderate size and larger, which has gone unnoticed
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because of the preponderance of united atom models and relatively short chain lengths in
alkane simulations.
The effect of electrostatic interactions on the acceptance ratio also caused efficiency prob-
lems. The alanine dipeptide simulations in Chapter 4 showed a similar, but smaller, effect,
with the addition of the electrostatic energy term causing a drop in acceptance ratio from
0.17 to 0.10. Strong long-distance interactions appear to present a problem for the CBMC
algorithm, an effect which can be explained by the short-sightedness of the method. Elec-
trostatic interactions may cause global changes in ligand conformation, an effect which biased
selection on an atom-by-atom basis will overestimate at short range and underestimate at long
range. These deviations from the desired statistics will result in the growth of low-weight
chains and a low acceptance ratio. The short-range overestimation effect can be compensated
by decreasing the contribution of electrostatics to the biasing potential, and considering the
balance of the energy in the acceptance rule. In the alanine dipeptide simulation this was
observed in the greater efficiency of the Ewald electrostatic evaluation method compared to a
simple calculation of pairwise Coulombic interaction energies. Recursive growth methods, as
mentioned in the introduction to Chapter 4, may be able to correct the problem of long-range
underestimation.
5.4.3 Prospects
There are a number of possible modifications to the simulation which might restore efficiency
to a workable level. Substitution of an essential hydrogen atom potential for the C22
all-atom potential, brings tripeptide simulations within reach, but systems much larger than
this are likely to cause difficulties. Drawing trial torsions from an appropriate non-uniform
distribution (for instance, based on a Ramachandran plot for backbone torsion angles) will
improve efficiency, and reduce the divergence of generated chains from Boltzmann statistics.
The number of degrees of freedom to which CBMC is applied could be reduced, as in
the published literature applying CBMC to peptides [54, 199] (see introduction Chapter 4).
Alternatively, only partial regrowths could be performed, rather than CBMC insertions of
complete chains. In both cases, this leads to the limitations noted in the introduction, and is
unsuitable for docking-type simulations. Equilibration is also much slower in this scheme, as
atoms in the middle of the chain are still regrown with low efficiency.
Recoil growth
An attractive alternative to CBMC with many similar characteristics is recoil growth [47, 48].
Recoil growth is a dynamic MC scheme which uses a biased growth technique reminiscent
of Meirovitch’s double scanning method [149, 150], with some resemblance to other recurs-
ive growth methods mentioned in the introduction to Chapter 4. There are a number of
advantages compared to CBMC, relevant for the efficiency problems that were observed in
this study. It is more efficient for long chains, and at higher densities, the latter making it
interesting for binding simulations. Two properties which should reduce the problem of low
acceptance ratios, are greater efficiency with a small number of trial moves, and early rejection
of chains with low Rosenbluth weights.
Recoil growth has some disadvantages. No efficient parallel algorithm is available [48].
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The calculation of excess chemical potential is less efficient than in CBMC. Even simple
recoil growth schemes have proven to be more difficult to implement than CBMC, and the
details for branched systems with complex bonded potentials have not yet been worked out.
Even so, recoil growth will undoubtedly be effective when applied to the conformational
analysis of simplified peptide models, and has a good chance of finding application in more
sophisticated peptide and protein simulation techniques.
Solvation
Given the aim of performing efficient simulations on peptides and proteins, the ability to deal
with (aqueous) solvation is essential for biologically relevant results. As mentioned above,
use of explicit water solvent molecules is not practical with normal CBMC, so some kind of
implicit or continuum representation of solvent effects is necessary. Both continuum electro-
static solvation methods and atomic-solvation-parameter-based models are suitable candidates,
and an example of the latter, generalised Born-surface area (GB/SA) [185], is available in the
T energy evaluation code.
A solvation potential can be easily added as a correction term in the MC acceptance
rule, in the same spirit that the Ewald correction is currently performed in B. As
evaluation of the solvation term is typically quite expensive, it is logical to perform it at this
point in the algorithm (following the discussion of efficiency optimisation in the previous
chapter). However, if the reduced acceptance ratio which results should be so low as to
seriously compromise the efficiency of the simulation (i.e. in the case where the solvation
term dominates the other terms in the forcefield), then some adjustment to the potential used
to generate trial moves will be necessary. A simple scaling of the electrostatic energy term
might be an effective remedy in such a case.
Elaborations of CBMC have been applied to simple fluid models consisting of binary
mixtures of differently-sized particles [32, 60, 61]. It is tempting to consider the possibility of
realistic explicit solvation simulations along these lines. The essence of the special MC move
used in these studies is the exchange of larger particles with multiple small particles occupying
an equivalent excluded volume. Another important development is an efficient scheme for
inserting and deleting ions from simulations of dipolar fluids [205], as the extensive ordering of
solvent molecules in response to charge makes unbiased approaches impractically inefficient.
It remains to be seen if such schemes will translate to efficient algorithms for more complex
peptide or protein models, but the possibilities for further research are obvious.
Chapter 6
General discussion
A number of methods for studying the interaction between protein and ligand came into play
in the course of this thesis. The intention was to apply and evaluate approaches which are
new in the context of drug design, and to consider the aspects of the molecular recognition
process which were apparent along the way. The two main subjects of investigation were
the role of protonation equilibria and electrostatic interactions, and the application of the
configurational bias Monte Carlo simulation technique. In evaluating the results of these
studies, both rational and empirical perspectives have a place, but given the patchy nature
of our theoretical understanding and our experimental knowledge, it is often hard to draw
conclusions.
The most important basis for understanding molecular recognition is the theory of equi-
librium processes embodied in (statistical) thermodynamics. There is also increasing interest in
kinetic processes, with wider scope than simply substrate–enzyme interactions, but for many
biochemical phenomena a purely equilibrium description is sufficient. The investigation of
proton linkage in Chapter 2 illustrates how macroscopic binding equilibria can be explained
by microscopic molecular models. An intuitive interpretation of the linkage concept which
is relevant for describing molecular recognition, is that the protonation state will change on
binding to optimize the electrostatic interactions between ligand and receptor, at least as far
as the excess chemical potential of the proton (i.e. pH) will permit. Interpretation of the
experimental data is difficult, particularly in the case of NMR titration experiments, and some
of the calculated pKa shifts appear to be spurious or unreliable, but the results make clear that
different ligands will induce different receptor protonation states on binding. These types of
predictions make it possible to better account for the protonation state and proton linkage
energies in subsequent modelling studies.
Computer programs to carry out pKa calculations of the type applied in Chapter 2 have
been developed by a number of groups since the method was introduced by Bashford and
Karplus in 1990 [21]. Systematic evaluations of the newest developments have not yet been
published, but progress is encouraging. Despite the general utility of the method, and the
presence of important pKa shifts in many well-known ligand–protein complexes, use of these
methods has not become routine. In part this is because of the disappointing accuracy which
could be achieved until recently, but the problem of unwieldy software which requires extens-
ive manual intervention even for simple calculations has also been a source of discouragement.
Incorporation of automated pKa calculation routines in general purpose modelling software,
such as WHAT IF [238], should help to popularize these methods.
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In Chapter 3 the calculated pKa shifts, along with experimental data on pH-related effects,
were used to fit a scoring function to experimental HIV-1 protease inhibitor activity data.
Inconsistencies in the calculated shifts, along with a lack of data regarding the free ligand pKa
values, prevented a quantitative prediction of linkage energies from being used in the analysis.
However, the inclusion in the regression equation of information concerning the assay pH
conditions, as well as a qualitative descriptor of the pKa shifts in the receptor, allowed a more
accurate scoring function to be found. This demonstrates that experimental data can be used
more effectively by more detailed consideration of information regarding assay conditions. It
also shows the importance of accurate, complete and consistent experimental data for model
building, and underlines the potential of new analytical techniques, such as surface plasmon
resonance and isothermal titration calorimetry, which can help in providing it.
One aim of the analysis was to investigate the role of electrostatics in molecular recognition
for a data set with predominantly hydrophobic ligands, and at the same time to consider the
possibility that the system of HIV-1 PR and peptidomimetic ligands presents an unusual case
for molecular recognition. The simple regression model cannot achieve the predictive accur-
acy of more elaborate methods parameterized for HIV-1 PR, but the results do not point to
exceptional properties. Further efforts to explain the activity of the one compound which fell
outside the analysis, MVT-101, are needed to round out the picture. The regression relation-
ships derived showed that electrostatic interactions weigh quite heavily in the balance of factors
which explain activity. This result suggests that general purpose scoring functions, where in
some cases (e.g. V [100]) electrostatic terms only make a minor contribution, might
be improved by use of more accurate data and methods in this respect.
As seen consistently in other studies using the continuum solvation electrostatics approx-
imation, the sum of electrostatic solvation and interaction energies opposed binding, a con-
tribution which must be overcome by other free energy terms, most importantly the hydro-
phobic effect. The prediction that systems with a net favourable electrostatic binding energy
can be engineered [44, 118] is a fascinating one in this context, and needs to be followed up
experimentally. A fine balance between opposing energy terms appears to be characteristic of
the binding process, and can also be observed experimentally in the phenomenon of entropy–
enthalpy compensation. An analogue exists in molecular recognition, where phenomena such
as pKa shifts, water binding, and global conformational change are seen to compensate for
more gross changes, such as the substitution of an interacting group. A consequence of this
principle is that predictions which partition the interaction energy into separate components
require individual contributing energy terms to be computed with exceptional accuracy in
order for the balance to be obtained with any confidence, considerably lowering the upper
bound on the reliability of such predictions.
Physically realistic free energy simulations avoid some of the difficulties inherent in scor-
ing approaches, but have their own limitations. Molecular dynamics and Metropolis Monte
Carlo simulations of ligand–receptor interactions converge very slowly, limiting the types of
predictions which can be made in a reasonable amount of computing time. The failure of
MD simulations on a nanosecond time scale to sufficiently sample the intramolecular dy-
namics of proteins has been highlighted in a detailed comparison between X-ray structures,
NMR structural and dynamics data, and MD trajectories [181]. Alternatives to MD which
allow equilibrium simulations with faster convergence are extremely desirable, and the success
of the configurational bias Monte Carlo technique in the simulation of alkane adsorption in
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zeolites suggested the possibility of biochemical applications. A CBMC implementation of
the C22 force field, described in Chapter 4, allows a well-characterised and accurate
potential function to be applied to simulations of peptides.
An application of CBMC to the docking of a tripeptide inhibitor of HIV-1 PR was tested
in Chapter 5. The particular characteristics of this system, namely the inaccessibility of the
active site, and the extensive flexibility of the ligand, make it difficult for many established
docking methods, and an interesting test case for the CBMC approach. FlexX, a successful
docking program based on an incremental construction algorithm, is able to dock the pep-
tidomimetic ligand VAC, with 17 rotatable bonds, to HIV-1 protease [188], and it would
be interesting to test its performance in docking the tripeptide. Successful docking of an
octapeptide in the MHC Class I molecule, a problem with similar features, required the use
of the dead-end elimination (DEE) approach, a series of algorithms specifically designed to
deal with the combinatorial problem of searching for low-energy peptide conformations [58].
CBMC was applied in combination with the parallel tempering sampling method, which has
been shown to improve the sampling of MD and MC by enhancing barrier crossing (interest-
ingly, parallel tempering seems to have been independently discovered in the applied statistics,
chemical physics and biomolecular simulation communities, more or less simultaneously).
A CBMC docking simulation was successful in finding a near-native docked conform-
ation, while attempts using the AutoDock software failed. The success of CBMC required
adjustment of the force field parameters, and docking was achieved in a short simulation by
fixing the position of the root atom in the binding site. CBMC did not display the hoped-for
efficiency, and the acceptance ratio of CBMC moves was very low even at high temperature.
In part, this was a result of the relatively constrained binding site, a situation similar to that
found in high density fluid simulations. CBMC is known to suffer from efficiency problems
under these conditions, and elaborations of the algorithm, such as the recoil growth proced-
ure [47, 48], are needed to improve matters significantly. However, the low efficiency also
appeared to be force field and model dependent, with efficiency decreasing with system size
at a much faster rate when highly branched models and the C potential was used,
than for the united-atom alkane models with which CBMC has been used previously. High
efficiency may require force fields tailored to the requirements of CBMC, plausible in the
light of advances in automated force field parameterization [175], or else modifications to the
algorithm. Alternatively, the use of simplified models, as seen in previous work on peptide
conformational analysis [54], is a proven route to efficient simulations.
Further development will be needed to make CBMC and related methods generally use-
ful for simulation of peptides and peptide binding. CBMC is unlikely to be competitive with
specialized methods for docking, but the possibilities for free energy simulations and conform-
ational sampling remain interesting. Other applications of CBMC in biomolecular simulation
are also possible. For example, lipid bilayer molecular dynamics simulations, well known
to equilibrate impractically slowly, can be supplemented with CBMC to improve conver-
gence [43]. Advancement in chain-growth algorithms for protein folding, which are closely
related to CBMC, also points towards possibilities for the future. It seems likely that “smart”
MC methods are likely to join MD as standard techniques in the simulation repertoire before
long.
The enzyme HIV-1 protease and its inhibitors served as the main test system in this work.
All proteins are not alike, and familiarity with the particularities of a given system of ligand
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and receptor is essential for successful modelling. This makes a focus on one example a mat-
ter of efficiency. But apart from this consideration, the explosion of attention devoted to
structure-based design of HIV-1 PR inhibitors, and the resultant overabundance of crystallo-
graphic data, makes it a unique object of study. The availability of large data sets of reasonable
accuracy and consistency, all relevant to one protein, has created a wonderful opportunity for
models to be evaluated and refined. HIV protease has also proven to provide fertile ground
for new developments such as knowledge-based potentials for the scoring of ligand–protein
interactions, and the investigation of the molecular basis of drug resistance [6]. HIV-1 PR
sequences from patients receiving antiretroviral therapy show polymorphism in 67 of the 99
amino acids [120] making this of vital therapeutic importance, as well as a fascinating subject
for investigation.
The observation that the devil is in the details, although a truism for scientific research,
sums up the contents of this thesis well. The consequences of many simple physical principles,
and the application of numerous established theoretical methods, still remain to be worked
out for biochemical system. The volume of experimental data in want of explanation is vast,
and growing ever more quickly. Luckily the devil has all the best tunes.
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Summary
Structure-based drug design is made possible by our understanding of molecular recognition.
The utility of this approach was apparent in the development of the clinically effective HIV-1
PR inhibitors, where crystal structures of complexes of HIV-1 protease and inhibitors gave
pivotal information. Computational methods drawing upon structural data are of increasing
relevance to the drug design process. Nonetheless, these methods are quite rudimentary and
significant improvements are needed. The aim of this thesis was to investigate techniques
which may lead to improved modelling of molecular recognition and a better ability to make
predictions about the binding affinity of ligands. The two main themes were the modelling
of acid–base titration behaviour of ligand and receptor, and the application of the simulation
technique of configurational bias Monte Carlo (CBMC). The studies were performed with
HIV-1 PR and its inhibitors as a model system.
Biological processes are influenced by the pH of the medium in which they take place.
Ligand–receptor binding equilibria are often thermodynamically linked to protonation changes
in ligand and/or receptor, as seen in the the binding of a number of HIV-1 PR inhibitors.
In Chapter 2, a series of sixteen continuum electrostatics pKa calculations of HIV-1 PR–
inhibitor complexes was done, in order to characterize the nature and size of these linkages.
The most important effects concern changes in the pKa of the enzyme active site aspartate
dyad. Large pKa shifts were predicted in all cases, and at least one of the two dyad pKas
became more basic on binding. At physiologically relevant pH, different ligands induced
different protonation states, with different tautomeric forms favoured. The fully deprotonated
form of the dyad was not significantly populated for any of the complexes. For about a third
of the complexes, both singly and doubly protonated forms were predicted to be populated.
The predicted predominant protonation states of MVT-101 and VX-478 were consistent with
previous theoretical studies. The size of the predicted pKa shifts for MVT-101 and XK263
differed from a previous study using similar methods. The paucity and ambiguity of available
experimental data makes it difficult to evaluate the results fully; however the tendency to
exaggerate shifts, as observed in other studies, appears to be present.
“Scoring” is the prediction of binding affinity from the structure of the ligand–receptor
complex, according to an empirical scheme. Scoring studies usually neglect or grossly simplify
the contribution of protonation equilibria to affinity, so in Chapter 3 proton linkage data was
included in a regression analysis of the HIV-1 PR complexes from Chapter 2. Parameters
previously shown to correlate with binding, namely electrostatic free energy changes and
buried surface areas, were the basis for the analysis, and terms describing proton linkage,
in the form of a correction for assay pH and an indicator variable for predicted dyad pKa
shift on binding, were also considered. The complex with MVT-101 was an outlier in the
analysis and was excluded. Further analysis demonstrated that the correction for assay pH
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made a significant contribution to the regression equation. Amendment of the parameters
for XK263 according to the available experimental data led to an improved regression in
which the term for calculated pKa shifts also made a significant contribution. The regression
equations obtained had the same form and similar coefficients to scoring functions of the
“master equation” type, and fit the experimental data with comparable accuracy.
More physically realistic simulations of ligand–receptor binding using the techniques of
molecular dynamics (MD) or Monte Carlo (MC) are potentially more accurate than scoring
function approaches. These methods are slow, so the alternative of CBMC, which has been
shown to give faster convergence for polymer simulations, was implemented for C22,
an all-atom protein force field (Chapter 4). The correctness of the implementation was
demonstrated by comparison with exact and stochastic dynamics (SD) results for individual
terms in the force field. The algorithm is more complex than those typically used with alkane
force fields, and this has possible consequences for the efficiency. CBMC was used to generate
a Ramachandran plot for the alanine dipeptide, and the results were found to be in agreement
with those generated by a SD simulation. Analysis of statistical errors suggests that CBMC
should be competitive with umbrella sampling for simulating conformational equilibria, par-
ticularly when the cost of non-bonded energy evaluations dominates the simulation.
CBMC can be applied to ligand–receptor binding, as demonstrated in grand canonical
simulations of alkane adsorption in zeolites. The more limited problem of finding the pre-
dominant bound conformation of a flexible ligand given a rigid protein receptor (i.e. “dock-
ing”) was treated in Chapter 5, using the example of a tripeptide inhibitor which binds to
HIV-1 PR. Attempts to perform the docking using the Metropolis MC/simulated annealing
and Lamarckian genetic algorithm methods implemented in the program AutoDock failed
to reproduce the native configuration (with runs on the order of two days execution time).
Docking using CBMC, combined with parallel tempering to further improve sampling, was
successful in finding the native binding mode, although this success was dependent on ad hoc
adjustments to the force field, and a priori knowledge of the ligand protonation state and bind-
ing site. The efficiency of the method was considerably lower than hoped, with problems
due to the force field- and model-dependent coupling between terms in the potential energy
function, and the “greedy” nature of the CBMC algorithm.
Various conclusions can be drawn from these studies. Chapters 2 and 3 provide evidence
of the importance of protonation equilibria in ligand–protein molecular recognition, and un-
derline the sizable contribution of electrostatic interactions to binding energies. In the face of
this finding, neglect of electrostatic terms, as often seen past studies, appears to be counterpro-
ductive. The scoring study also shows how experimental data can be used more effectively if
factors such as assay conditions are carefully taken into account. Implementation of CBMC for
a widely-used protein force field and application of the algorithm to docking (Chapters 4 and
5) represents a proof of concept for a broadly useful simulation technique. Further work will
be required to find the right niche for CBMC and fully explore the potential of this and re-
lated techniques. A final point is the demonstrated utility of the HIV-1 PR test system which
formed the focus of the studies. Abundant structural data has enabled many new approaches
to be tested, and further insights are expected from the analysis of unusual cases, such as the
anomalous results for MVT-101. As well as the question of scoring, studies of mutation and
resistance are likely to attract considerable interest in the future.
Samenvatting
Structure-based drug design wordt mogelijk gemaakt door inzicht in moleculaire herkenning.
Het nut van deze aanpak werd aangetoond tijdens de ontwikkeling van de HIV-1 protease
remmers, door de belangrijke inbreng van HIV-1 PR–remmer kristal structuren. Op structuur
data gebaseerde computer methodes zijn van toenemend belang voor de geneesmiddelontwik-
keling. Desalniettemin zijn deze technieken tamelijk grof en verdere verbeteringen zijn nodig.
Het doel van dit proefschrift was om technieken te onderzoeken die tot verbeterde nabootsing
van moleculaire herkenning kunnen leiden en daardoor tot nauwkeuriger voorspellingen van
de bindingsaffiniteit van liganden voor eiwitten. De twee hoofdthema’s waren de modeling
van zuur–base titratie gedrag van ligand en receptor, en de toepassing van de simulatietechniek
configurational bias Monte Carlo (CBMC). Het werk werd uitgevoerd met gebruik van HIV-1
PR en remmers als model.
Biologische processen worden beı¨nvloed door de pH van de omgeving waarin zij plaats
vinden. Ligand–receptor bindingsevenwichten zijn vaak gekoppeld aan veranderingen in pro-
tonatie toestand van ligand en/of receptor, b.v. in het geval van het bindingsgedrag van
bepaalde HIV-1 PR remmers. In Hoofdstuk 2 werd een reeks continuum electrostatics pKa be-
rekeningen van HIV-1 PR–remmer complexen uitgevoerd, om de aard en mate van deze
koppelingen te bepalen. De allerbelangrijkste verschijnselen hebben betrekking tot verande-
ringen van de pKa’s van de aspartaat dyad in de active site. Grote pKa verschuivingen werden
voorspeld in alle gevallen, en minstens een van de twee pKa’s werd basischer na binding. Bij
fysiologische pH geven verschillende liganden aanleiding tot verschillende protonatie toestan-
den, met verschillende tautomerisatie. Een volledige gedeprotoneerde dyad werd alleen met
een uiterst geringe waarschijnlijkheid terug gevonden in de resultaten. In ongeveer een derde
van de gevallen werden zowel enkel als dubbel geprotoneerde toestanden gevonden. De meest
voorkomende protonatie toestand van MVT-101 en VX-478 kwam overeen met eerder ge-
publiceerde resultaten. De mate van de pKa verschuivingen van MVT-101 en XK263 was niet
gelijk aan de resultaten van een ander onderzoek dat overeenkomstige methodes gebruikte.
De schaarste en onduidelijkheid van beschikbare experimentele gegevens maken het moeilijk
om de voorspellingen volledig te controleren. Er is wel een trend naar overdrijving van de
verschuivingen, zoals in andere onderzoeken wordt beschreven.
“Scoring” betekent het voorspellen van bindingsaffiniteit door middel van een empirische
evaluatie van de structurele aard van het ligand–receptor complex. Scoring benaderingen ne-
geren meestal de bijdrage van het protonatieevenwicht aan de affiniteit, en daarom werden
in Hoofdstuk 3 protonatiekoppelingsdata toegevoegd aan een regressie analyse van de HIV-1
PR complexen uit Hoofdstuk 2. Parameters waarvan eerder een correlatie met bindingsaffi-
niteit werd aangetoond, b.v. electrostatische vrije energie veranderingen en veranderingen in
moleculaire oppervlakte, vormden de grondslag van de analyse, en termen die met protona-
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tiekoppeling te maken hebben, met name een correctie op basis van assay pH en een indicator
variabele voor dyad pKa verschuiving, werden ook meegenomen. Het complex met MVT-
101 was een uitbijter en werd buiten beschouwing gelaten. Nadere statistische analyse liet zien
dat de assay pH correctie aantoonbaar aan de regressie bijdroeg. De regressievergelijkingen die
gevonden werden hadden dezelfde vorm en vergelijkbare coe¨fficie¨nten in relatie tot scoring
functies van het “master equation” type, en kwamen even goed met de experimentele data
overeen.
Een meer gedetailleerde nabootsing van de werkelijkheid door middel van moleculaire
dynamica (MD) of Monte Carlo (MC) simulaties kan nauwkeuriger schattingen van bin-
dingsconstanten opleveren dan scoring functie benaderingen. Deze methodes zijn helaas zeer
langzaam, en daarom werd CBMC, dat een snelle convergentie laat zien bij polymeer si-
mulaties, als alternatieve sampling procedure geı¨mplementeerd voor het C22 all-atom
eiwit krachtveld (Hoofdstuk 4). De betrouwbaarheid van de implementatie werd bewezen
door resultaten te vergelijken met zowel exacte als stochastische dynamica (SD) resultaten
met betrekking tot afzonderlijke termen uit het krachtveld. Dit krachtveld vereist een algo-
ritme met meer complexiteit in vergelijking met typische alkaan krachtveld toepassingen, wat
mogelijk gevolgen heeft met betrekking tot de efficie¨ntie. CBMC werd gebruikt om een
Ramachandran grafiek te maken voor alanine dipeptide, en de resultaten kwamen goed over-
een met SD resultaten. Analyse van de statistische fouten geeft aan dat CBMC een waardige
concurrent zou zijn voor umbrella sampling, in het bijzonder in het geval dat de kosten van
non-bonded energie evaluaties overheersen.
CBMC kan op het ligand–receptor binding probleem worden toegepast, zoals in grand
canonical simulaties van alkaan adsorptie aan zeolieten werd gezien. Makkelijker is het vin-
den van de meest voorkomende gebonden conformatie van een flexibele ligand, gegeven
een rigide receptor (d.w.z. “docking”), een probleem dat in Hoofdstuk 5 werd behandeld
met het voorbeeld van een tripeptide HIV-1 PR remmer. Docking pogingen met de Me-
tropolis MC/simulated annealing en Lamarckian genetic algorithm methodes van het programma
AD slaagden er niet in om de juiste configuratie terug te vinden. CBMC docking,
in combinatie met parallel tempering om de sampling verder te verbeteren, kwam wel op een
acceptabel antwoord, hetgeen van voorkennis over de protonatie toestand en bindingsplek
en ook speciale aanpassingen van het krachtveld afhing. De efficie¨ntie van de methode was
merkbaar minder dan verwacht, met problemen mede veroorzaakt door de krachtveld- en
model-afhankelijke koppeling tussen termen in de potential energy function, en de “greedy”
aanpak van het CBMC algoritme.
Verschillende conclusies kunnen worden getrokken uit dit werk. Hoofdstukken 2 en 3
wijzen op het belang van protonatieevenwichten in ligand–eiwit moleculaire herkenning, en
onderschrijven de behoorlijke bijdrage van electrostatische interacties aan bindingsenergiee¨n.
Het scoring onderzoek laat ook zien hoe experimentele gegevens beter kunnen worden be-
nut wanneer zorgvuldig rekening wordt gehouden met factoren zoals assay omstandigheden.
Implementatie van CBMC voor een veelgebruikt eiwit krachtveld en de toepassing hiervan
op docking (Hoofdstukken 4 en 5) laten zien dat CBMC een breed toepasbare simulatie-
techniek is. Uit nader onderzoek moet blijken welke niche het beste is voor CBMC en wat
voor efficie¨nties haalbaar zijn. Een laatste punt is het aantoonbare nut van het HIV-1 PR
test systeem dat hier gebruikt werd. Een schat aan structurele data laat toe om vele nieuwe
technieken te testen, en nog meer inzichten zijn te verwachten uit analyse van afwijkende
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gevallen, b.v. de uitbijter MVT-101. Naast de scoring problematiek zullen in de toekomst
studies met betrekking tot mutatie en resistentie van groot belang zijn.
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